

SOURCE	Homo sapiens (human)	TITLE	Target genes for the diagnosis and treatment of cancer
ORGANISM	Homo sapiens	JOURNAL	Patent: WO 200403020-A 62 06-MAY-2004, Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE)
REFERENCE	1 (bases 1-2465)	FEATURES	1. Location/Qualifiers
AUTHORS	Demura,H., Nomura,K., Shimizu,S., Raari,T.H. and Hisakawa,Y.	Source	1. . 2691
JOURNAL	HOKEN KAGAKU KENKYUSHO:KK		/organism="Homo sapiens"
COMMENT	OS Homo sapiens (human)		mol_type="unassigned DNA"
PN	JP 1996322577-A/1		/db_xref="taxon:9606"
PD	10-DEC-1996		1. . 2691
PP	01-DEC-1995		/note="M11717"
PI	1 TABURIYU HANKINZU, PI HISAKAWA YOSHIZO	ORIGIN	
PI	PC C12N15/09, C12P21/02, C12Q1/68;	Query Match	100 %; Score 215; DB 6; Length 2691;
CC	CC strandness: Double;	Best Local Similarity	100 %; Pred. No. 1.1e-46;
CC	CC topology: Linear;	Matches	215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
PH	PH Key	Source	1 ATAACGGCTAGCTGAGGAGTGTCTGGACAGTCCACTACCTTTGAGAGTGTACTCCC 60
FT	FT source		274 ATAACGGCTAGCTGAGGAGTGTCTGGACAGTCCACTACCTTTGAGAGTGTACTCCC 333
FT	FT /organism="Homo sapiens"		61 GTGTGTCAGCTTCCAGAGCGAACCTGGGGTGGAGCACCGCCGGCTGAGTT 120
FT	FT /feature="CDS"		334 GTGTGCCAAGCTTCCAGAGCGAACCTGGGGTGGAGCACCGCCGGCTGAGTT 393
FT	FT mutation		121 CCGGCGCCGAGGACGAGCTCTCCAGGATCCAGTGTCCGGTTCCAGGCCCAA 180
FT	FT /product="HS70"		394 CCGGCGCCGAGGACGAGCTCTCCAGGATCCAGTGTCCGGTTCCAGGCCCAA 453
FEATURES	FEATURES Source		181 TCTCAGGCCAGCCAGAGAGCAGGGACCC 215
	1. . 2465		454 TCTCAGGCCAGCCAGAGAGCAGGGACCC 488
	/organism="Homo sapiens"		
	/mol_type="genomic DNA"		
	/db_xref="taxon:9606"		
ORIGIN		RESULT 10	
Query Match	100 %; Score 215; DB 6; Length 2465;	LOCUS	Q818823
Best Local Similarity	100.0%; Pred. No. 1.1e-46;	DEFINITION	CQ818823
Matches	215; Conservative 0; Mismatches 0;	ACCESSION	Sequence 6 from Patent WO2004039412.
Indels	0;	VERSION	CQ818823
Gaps	0;	KEYWORDS	CQ818823.1 GI:48427426
		SOURCE	
QY	1 ATAACGGCTAGCTGAGGAGTGTCTGGACAGTCCACTACCTTTGAGAGTGTACTCCC 60	ORGANISM	Homo sapiens (human)
Db	48 ATAACGGCTAGCTGAGGAGTGTCTGGACAGTCCACTACCTTTGAGAGTGTACTCCC 107		Homo sapiens; Mammalia; Chordata; Craniata; Vertebrata; Euteleostomi; Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
QY	61 GTGTGCCAAGCTTCCAGAGCGAACCTGGGGTGGAGCACCGCCGGCTGAGTT 120	REFERENCE	1 Doiron,B., Pownall,S., Cheung,A. and Hsu,E.
Db	108 GTGTGCCAAGCTTCCAGAGCGAACCTGGGGTGGAGCACCGCCGGCTGAGTT 167	AUTHORS	
QY	121 CCGGCGCCGAGGACGAGCTCTCCAGGATCCAGTGTCCGGTTCCAGGCCCAA 180	TITLE	
Db	168 CCGGCGCCGAGGACGAGCTCTCCAGGATCCAGTGTCCGGTTCCAGGCCCAA 227	JOURNAL	
QY	181 TCTCAGGCCAGCCAGAGAGCAGGGACCC 215	FEATURES	
Db	228 TCTCAGGCCAGCCAGAGAGCAGGGACCC 262	Source	1. . 2691
RESULT 9			/organism="Homo sapiens"
Q812310			/mol_type="unassigned DNA"
LOCUS	CQ812310		/db_xref="taxon:9606"
DEFINITION	Sequence 62 from Patent WO2004039412.		
ACCESSION	CQ812310		
VERSION	CQ812310.1 GI:47601930		
KEYWORDS			
SOURCE	Homo sapiens (human)	ORIGIN	
ORGANISM	Homo sapiens	Query Match	100 %; Score 215; DB 6; Length 2691;
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	Best Local Similarity	100.0%; Pred. No. 1.1e-46;
AUTHORS	Wittig,R., Poustka,A., Mollenhauer,J. and Schadendorf,D.	Matches	215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

	COMMENT	Original source text: Homo sapiens DNA. [2] revises [1]. Sequence revised July 30, 1992.
	FEATURES	[2] location/Qualifiers
Qy	181 TCTCAGAGCCGAGCCGAGAGAGCAGGGACCGC 215	
Db	454 TCTCAGAGCCGAGCCGAGAGAGCAGGGACCGC 488	
RESULT 11		
AR262810	AR262810 2691 bp DNA linear PAT 29-JAN-2003	
DEFINITION	Sequence 1 from patent US 6331388.	
ACCESSION	AR262810	
VERSION	AR262810.1 GI:28074512	
KEYWORDS		
SOURCE	Unknown.	
ORGANISM	Unclassified.	
REFERENCE	1 (bases 1 to 2691)	
AUTHORS	Malkovsky, M. and Wells, A. D.	
TITLE	Immune response enhancer	
JOURNAL	Patent: US 6331388-A 1 18-DEC-2001;	
FEATURES	Location/Qualifiers	
Source	1. 2691 /organism="unknown" /mol_type="genomic DNA"	
ORIGIN		
Query	Match 100.0%; Score 215; DB 6; Length 2691;	
Best Local Similarity 100.0%; Pred. No. 1.1e-46; Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Db	274 ATAACGGCTAGCTGAGGAGCTGCTGGAGACTTCACACTACCTTTGAGAGTGACTCCC 60	
Qy	61 GTTGTCCTCAAGGCTCCAGAGCAGCTGCTGGGCTGAGACACCGCGCTGAGTT 120	
Db	334 GTTGTCCTCAAGGCTCCAGAGCAGCTGCTGGGCTGAGACACCGCGCTGAGTT 393	
RESULT 12		
HUMHSP70D	HUMHSP70D 2691 bp DNA linear PRI 08-NOV-1994	
DEFINITION	Human heat shock protein (hsp 70) gene, complete cds.	
ACCESSION	M11717 M15432	
VERSION	M11717.1 GI:184416	
KEYWORDS	HSP70 gene; heat shock protein.	
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
REFERENCE	1 (bases 1 to 2691)	
AUTHORS	Hunt, C. and Morimoto, R.I.	
TITLE	Conserved features of eukaryotic hsp70 genes revealed by comparison with the nucleotide sequence of human hsp70	
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 82 (19), 6455-6459 (1985)	
MEDLINE	86016721	
PUBMED	3931075	
REFERENCE	2 (bases 94 to 293)	
AUTHORS	Morgan, W.D., Williams, G.T., Morimoto, R.I., Greene, J., Kingston, R.E., and Tjian, R.	
TITLE	Two transcriptional activators, CCAAT-box-binding transcription factor and heat shock transcription factor, interact with a human hsp70 gene promoter	
JOURNAL	Mol. Cell. Biol. 7 (3), 1129-1138 (1987)	
MEDLINE	87172780	
PUBMED	3561411	
RESULT 13		
AB018045	AB018045 4360 bp DNA linear PRI 14-APR-2000	
LOCUS		
DEFINITION	Homo sapiens HSP70-1 gene for heat shock protein 72, spliced variant, partial cds.	
ACCESSION	AB018045	
VERSION	AB018045.1 GI:4691417	
KEYWORDS	HSP70-1; heat shock protein 72; HSP70-Hom; alternative splicing.	
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
REFERENCE	1 (sites)	
AUTHORS	Shimizu, S., Nomura, K., Ujihara, M. and Demura, H.	
TITLE	An additional exon of stress-inducible heat shock protein 70 gene (HSP70-1)	
JOURNAL	Biochem. Biophys. Res. Commun. 257 (1), 193-198 (1999)	
MEDLINE	99194576	

PUBLISHED	ACCESSION
2 (bases 1 to 4360)	SS2686
Nonura, K. and Shimizu, S.	SS2686.1
Direct Submission	
COMMENT	
JOURNAL	
Submitted (27-SEP-1998) Kaoru Nonura, Tokyo Women's Medical University, Department of Medicine 2; 8-1 Kawadacho, Shinjuku-ku, Tokyo 162-8666, Japan (E-mail:nonura7@sparky.ne.jp, Tel:81-3-3355-8111(ex.39223), Fax:81-3-3355-6475)	
Sequence updated (26-Oct-1998).	
FEATURES	
source	
1. 4360	
/organism="Homo sapiens"	
/mol type="genomic DNA"	
/db_xref="taxon:9606"	
/chromosome="6"	
/map="6p21.3"	
gene	
complement(1..196)	
/gene="HSP70-1om"	
/gene="HSP70-1om"	
gene	
complement(1..196)	
/gene="HSP70-1"	
exon	
2323 .. 2679	
/gene="HSP70-1"	
gene	
/note="alternative splicing"	
/number=1	
join(2632 .. 2679,3955..>4360)	
CDS	
/db_xref="GI:4691418"	
/gene="HSP70-1"	
/note="spliced variant"	
codon_start=1	
/product="heat shock protein 72"	
/protein_id="BA7735.1"	
/db_xref="taxon:9606"	
/translation="MKGWPQVNDQDKPKVQSYKGETKAFYRPEIISNVLTHNKEI	
AEAVIGYPVNTAVIYTNPAYVQAGVAGLNWIRIINPTAAIAVGLDRT	
GKGRNVLVFLDGGTFFDVSILIDGIEFVKAFTAGDTHGGEDFDNRQ"	
exon	
3443 .. 3954	
/gene="HSP70-1"	
/note="alternative splicing	
transcription usually starts from exon 2"	
/number=2	
3955 .. >4360	
/gene="HSP70-1"	
/note="alternative splicing"	
/number=3	
ORIGIN	
Query Match	100.0%; Score 215; DB 9; Length 4360;
Best Local Similarity	100.0%; Pred. No. 1..1e-46;
Matches	215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 ATAAACGGTAGCTGAGGAGCTGCTGGACAGTCCTACCTTTGAGAGTGACTCC
Db	274 ATAACGGCTAACCTGAGAGCTGCGGAGCTACCTTTGAGAGTGACTCC
QY	61 GTGTGCCAAAGCTTCCAGAGGAACTCTGGCTCGAGGACCGCGCTGAGTTR
Db	334 GTGTGCCAAAGGCTTCCAGAGGAACTCTGGCTCGAGGACCGCGCTGAGTTR
QY	121 CGGGCGCCGAAAGGAGCGACTCTTCGGATCCAGTGTTCGGTTCAAGCCCCAA
Db	394 CGGGCGCCGAAAGGAGCGACTCTTCGGATCCAGTGTTCGGTTCAAGCCCCAA
QY	181 TCTCAGAGGCCAGGCCAGAGAGCAGGGACCGC 215
Db	454 TCTCAGAGGCCAGGCCAGAGAGCAGGGACCGC 488
ORIGIN	
Query Match	100.0%; Score 215; DB 9; Length 4360;
Best Local Similarity	100.0%; Pred. No. 1..1e-46;
Matches	215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 ATAAACGGTAGCTGAGGAGCTGCTGGACAGTCCTACCTTTGAGAGTGACTCC
Db	3434 ATAACGGCTAACCTGAGAGCTGCGGAGCTACCTTTGAGAGTGACTCC
QY	61 GTGTGCCAAAGCTTCCAGAGGAACTCTGGCTCGAGGACCGCGCTGAGTTR
Db	3494 GTGTGCCAAAGCTTCCAGAGGAACTCTGGCTCGAGGACCGCGCTGAGTTR
QY	121 CGGGCGCCGAAAGGAGCGACTCTTCGGATCCAGTGTTCGGTTCAAGCCCCAA
Db	3554 CGGGCGCCGAAAGGAGCGACTCTTCGGATCCAGTGTTCGGTTCAAGCCCCAA
QY	181 TCTCAGAGGCCAGGCCAGAGAGCAGGGACCGC 215
Db	3614 TCTCAGAGGCCAGGCCAGAGAGCAGGGACCGC 3648
RESULT	14
SS2686	SS2686
LOCUS	S52686
DEFINITION	HLA class III polymorphic region: HSP70-1=heat shock protein 70 (5' region) [human, PGr, Wt49, Wt51, Genomic, 488 nt].
ORIGIN	
FEATURES	
source	
/organism="Homo sapiens"	
/mol type="unassigned DNA"	
/db_xref="taxon:9606"	
ORIGIN	
RESULT	15
SS2686	C080661
LOCUS	C080661
DEFINITION	Sequence 111 from Patent WO2004035803.
ACCESSION	C080661
VERSION	C080661.1
REFERENCE	GI:47112043
ORGANISM	Homo sapiens (human)
KEYWORDS	Homo sapiens; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Eukaryota; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS	Fokkens, J., Harbeck, N., Koening, T., Maier, S., Martens, J., Model, F., Nimmrich, I., Rujan, T., Schmitt, A., Schmitt, M., Look, M. P. and Marx, A.
TITLE	Method and nucleic acids for the improved treatment of breast cell
JOURNAL	Patent: WO 2004035803-A 111 29 APR-2004;
FEATURES	Epigenomics AG (DE)
source	
/organism="Homo sapiens"	

Query Match 99.5%; Score 214; DB 6; Length 5387;
Best Local Similarity 100.0%; Pred. No. 2e-46;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 ATAACGGCTACGCTGAGGAGCTGCTGGACAGTCCACTACCTTTTGAGAGTGACTCCC 60
Db 1982 ATAACGGCTAGCTGAGGAGTGCTGGACAGTCCACTACCTTTTGAGAGTGACTCCC 2041
Qy 61 GGTGTCCTAACGCTTCCAGGGGACCTGTTGGGGTGAGGACGGGCGGTGAGTT 120
Db 2042 GGTGTCCTAACGCTTCCAGGGGACCTGTTGGGGTGAGGACGGGCGGTGAGTT 2101
Qy 121 CGGGCGTCCGGAGGACCGAGCTCTCGGGATCCAGTTCCGGTTCAAGCCCCAA 180
Db 2102 CGGGCGTCCGGAGGACCGAGCTCTGGGATCCAGTTCCGGTTCAAGCCCCAA 2161
Qy 181 TCTCAGGCCAGGCCAGAGAGCAGGGAAACG 214
Db 2162 TCTCAGGCCAGGCCAGAGAGCAGGGAAACG 2195

Search completed: February 11, 2005, 08:35:10
Job time : 1055 secs

1.0 Pago Baja (18%)

CC bacterial, viral and parasitic infections and also for treating immune-
 CC related diseases and for contraceptive purposes. In addition, the present
 CC sequence may be useful in gene therapy of various disorders such as
 CC cancer, cardiovascular disorders and cystic fibrosis
 XX

: SQ Sequence 215 BP; 41 A; 71 C; 63 G; 40 T; 0 U; 0 Other;
 Query Match 100.0%; Score 215; DB 3; Length 215;
 Best Local Similarity 100.0%; Pred. No. 6. 6e-55; Mismatches 0; Indels 0; Gaps 0;
 Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 ATAACGCTAGCTGAGGAGCTCTGCACAGTCCACTACCTTTGAGAGTGAATCCC 60
 1 ATAACGCTAGCTGAGGAGCTCTGCACAGTCCACTACCTTTGAGAGTGAATCCC 60
 Db 1 ATAACGCTAGCTGAGGAGCTCTGCACAGTCCACTACCTTTGAGAGTGAATCCC 60
 1 ATAACGCTAGCTGAGGAGCTCTGCACAGTCCACTACCTTTGAGAGTGAATCCC 60
 Qy 61 GTTGTGTCCTAACGCTTCCAGCAGGAACTGTGGGCTGAGCAGACAGTCCACTACCTTTGAGAGTGAATCCC 60
 61 GTTGTGTCCTAACGCTTCCAGCAGGAACTGTGGGCTGAGCAGACAGTCCACTACCTTTGAGAGTGAATCCC 60
 Db 61 GTTGTGTCCTAACGCTTCCAGCAGGAACTGTGGGCTGAGCAGACAGTCCACTACCTTTGAGAGTGAATCCC 60
 61 GTTGTGTCCTAACGCTTCCAGCAGGAACTGTGGGCTGAGCAGACAGTCCACTACCTTTGAGAGTGAATCCC 60
 Qy 121 CGGGCGGCGGAGGAGCCAGCTTCTGGGATCCAGTGTCCGTTCAAGCCCCAA 180
 121 CGGGCGGCGGAGGAGCCAGCTTCTGGGATCCAGTGTCCGTTCAAGCCCCAA 180
 Db 121 CGGGCGGCGGAGGAGCCAGCTTCTGGGATCCAGTGTCCGTTCAAGCCCCAA 180
 121 CGGGCGGCGGAGGAGCCAGCTTCTGGGATCCAGTGTCCGTTCAAGCCCCAA 180
 Qy 181 TCTCAGAGCCGAGCCAGAGAGGAGGAGGAGCC 215
 181 TCTCAGAGCCGAGCCAGAGAGGAGGAGCC 215
 Db 181 TCTCAGAGCCGAGCCAGAGAGGAGGAGCC 215

RESULT 2
 AAA94756
 ID AAA94756 standard; mRNA; 215 BP.
 AC
 XX
 DT 19-JAN-2001 (first entry)
 XX
 DE Human HSP70A 5' untranslated region mRNA sequence.
 XX
 KW Human; HSP70A; 5' UTR; untranslated region; heat shock protein;
 KW translation efficiency; vaccine; bacterial; viral; parasitic infection;
 KW immune-related disease; contraceptive; gene therapy; cancer;
 KW cardiovascular disorder; cystic fibrosis; ss.
 OS Homo sapiens.
 XX
 PN WO20053785-A2.
 XX
 PD 14-SEP-2000.
 XX
 PP 09-MAR-2000; 2000WO-EP002031.
 XX
 PR 11-MAR-1999; 99GB-00005498.
 XX
 PA (GLAXO GROUP LTD.
 XX
 PI Coste HJ, Ellis JH;
 XX
 DR WPI; 2000-594331/56.
 XX
 PT Human heat shock protein 5' untranslated region (UTR) transcribed to
 PT provide an RNA molecule having UTR that increases translation efficiency
 PT of polypeptides, useful for treating deficiency in expression of the
 PT polypeptide.
 PS Disclosure; Page 3; 44pp; English.

The present sequence is the 5' untranslated region (UTR) mRNA of human heat shock protein (Hsp) 70A gene. This sequence has a high potential to form secondary structures. This sequence can be used to increase the translation efficiency of a polypeptide. The present sequence may be useful in therapeutic or prophylactic vaccination for preventing bacterial, viral and parasitic infections and also for treating immune-related diseases and for contraceptive purposes. In addition, the present

CC sequence may be useful in gene therapy of various disorders such as
 CC cancer, cardiovascular disorders and cystic fibrosis
 XX

: SQ Sequence 215 BP; 41 A; 71 C; 63 G; 0 T; 40 U; 0 Other;
 Query Match 100.0%; Score 215; DB 3; Length 215;
 Best Local Similarity 81.4%; Pred. No. 6. 6e-55; Mismatches 0; Indels 0; Gaps 0;
 Matches 175; Conservative 40; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 ATAACGCTAGCTGAGGAGCTCTGCACAGTCCACTACCTTTGAGAGTGAATCCC 60
 1 ATAACGCTAGCTGAGGAGCTCTGCACAGTCCACTACCTTTGAGAGTGAATCCC 60
 Db 1 ATAACGCTAGCTGAGGAGCTCTGCACAGTCCACTACCTTTGAGAGTGAATCCC 60
 1 ATAACGCTAGCTGAGGAGCTCTGCACAGTCCACTACCTTTGAGAGTGAATCCC 60
 Qy 61 GTTGTGTCCTAACGCTTCCAGCAGGAACTGTGGGCTGAGCAGACAGTCCACTACCTTTGAGAGTGAATCCC 60
 61 GTTGTGTCCTAACGCTTCCAGCAGGAACTGTGGGCTGAGCAGACAGTCCACTACCTTTGAGAGTGAATCCC 60
 Db 61 GTTGTGTCCTAACGCTTCCAGCAGGAACTGTGGGCTGAGCAGACAGTCCACTACCTTTGAGAGTGAATCCC 60
 61 GTTGTGTCCTAACGCTTCCAGCAGGAACTGTGGGCTGAGCAGACAGTCCACTACCTTTGAGAGTGAATCCC 60
 Qy 121 CGGGCGGCGGAGGAGCCAGCTTCTGGGATCCAGTGTCCGTTCAAGCCCCAA 180
 121 CGGGCGGCGGAGGAGCCAGCTTCTGGGATCCAGTGTCCGTTCAAGCCCCAA 180
 Db 121 CGGGCGGCGGAGGAGCCAGCTTCTGGGATCCAGTGTCCGTTCAAGCCCCAA 180
 121 CGGGCGGCGGAGGAGCCAGCTTCTGGGATCCAGTGTCCGTTCAAGCCCCAA 180
 Qy 181 TCTCAGAGCCGAGCCAGAGAGGAGGAGCC 215
 181 TCTCAGAGCCGAGCCAGAGAGGAGGAGCC 215
 Db 181 TCTCAGAGCCGAGCCAGAGAGGAGGAGCC 215

RESULT 3
 ABA99140
 ID ABA99140 standard; cDNA; 2691 BP.
 AC
 XX
 DT 23-MAY-2002 (first entry)
 XX
 DE Human hsp72 encoding sequence.
 XX
 KW Human; hsp72; heat shock protein; cytostatic; antibacterial;
 KW antiparasitic; MHC class I; ss.
 OS Homo sapiens.
 PN US63311388-B1.
 XX
 PD 18-DEC-2001.
 XX
 PP 17-OCT-1997; 97US-00955565.
 XX
 PR 17-OCT-1997; 97US-00955565.
 XX
 PA (WISC) WISCONSIN ALUMNI RES FOUND.
 XX
 PI Malkovský M, Wells AD;
 XX
 DR WPI; 2002-138391/18.
 XX
 PT Increasing expression of an MHC class I molecule in a cell, useful in
 PT increasing antigen presentation and enhancing immune recognition of cells
 PT infected with pathogens, by expressing a heat shock protein introduced by
 XX
 PS Example 1; Fig 1; 89pp; English.
 XX
 CC This invention relates to increasing expression of an MHC class I
 CC molecule in a target cell, infected with a pathogen that is processed by
 CC the MHC class I endogenous pathway. The method of expressing a HSP is
 CC achieved by the introduction of an expression vector encoding HSP to
 CC produce a transfected cell with increased expression of at least one MHC
 CC class I molecule. The method is cytostatic, antibacterial and
 CC antiparasitic. The method can be used to increase expression of an MHC
 CC class I molecule in a target cell and to increase presentation of an
 CC antigen on a cell surface by an MHC class I molecule. The method can
 CC enhance the immunogenicity of the endogenous antigen in vivo, by
 CC enhancing the generation of antibodies to an otherwise poorly immunogenic

The invention relates to detecting (GA), by detecting the level of expression of gene(s) (Gs), activation DNA chip analysis as given in the specification, and comparing the expression level to an expression level in an unactivated GC, where differential expression of Gs is indicative of GCA. Also included are modulating (M2) GA by contacting GC with an agent that alters the expression of at least one gene in Gs; (2) screening (M3) for an agent capable of modulating GCA or an inflammation (especially chronic) in a tissue, an allergic response in a subject, exposure of a subject to a pathogen or sterile inflammatory disease using the gene expression profile; (3) detecting (M4) an inflammation (especially chronic) in a tissue, an allergic response in a subject, exposure of a subject to a pathogen or sterile inflammatory disease, by detecting the level of expression in a sample of the tissue of gene(s) from Gs, where the level of expression of the gene is indicative of inflammation; (4) treating (M5) an inflammation (especially chronic) or in a tissue, an allergic response in a subject, exposure of a subject to a pathogen or sterile inflammatory disease, by contacting a tissue having inflammation with an agent that modulates the expression of gene(s) from Gs in the tissue. M1 is useful for detecting GCA, M2 is useful for modulating GA, M3 is useful for screening an agent capable of modulating GCA preferably in an inflammation in a tissue; M4 is useful for detecting an inflammation (especially chronic) in a tissue, an allergic response in a subject, exposure of a subject to a pathogen or sterile inflammatory disease (e.g. psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, thrombosis, cardiac reperfusion injury, renal reperfusion injury, AIDS, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, periodontal disease; also bacterial infection, viral infection, parasitic infection, protozoal infection, fungal infection and M5 is useful for treating one of the above conditions. The present sequence represents a gene differentially expressed in granulocytes. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp://wipo.int/pub/published_pct_sequences

OS Homo sapiens.
 XX
 PN WO2003062395-A2.
 XX
 PD 31-JUL-2003.
 XX
 PP 17-JAN-2003; 2003WO-US001981.
 XX
 PR 18-JAN-2002; 2002US-035061P.
 XX
 PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX
 PI Huang F, Fairchild CR, Lee FY, Shaw P;
 XX
 DR WPI; 2003-636735/60.
 XX
 DR P-PSDB; ADB14137.
 XX
 PT New polynucleotides and polypeptides for predicting the activity of
 PT compounds that interact with protein tyrosine kinases and/or protein
 tyrosine kinase pathways.
 XX
 PS Claim 2; SEQ ID NO 133; 139pp; English.
 CC The present invention describes a predictor set comprising a plurality of
 CC polynucleotides or polypeptides whose expression pattern is predictive of
 CC the response of cells to treatment with a compound that modulates protein
 CC tyrosine kinase activity or members of the protein tyrosine kinase
 CC pathway. Also described: (1) predicting whether a compound is capable of
 CC modulating the activity of cells, comprising obtaining a sample of cells,
 CC determining whether the cells express a plurality of markers, and
 CC correlating the expression of the markers to the compound's ability to
 CC modulate the activity of the cells; (2) a plurality of cell lines for
 CC identifying polynucleotides and polypeptides whose expression levels
 CC correlate with compound sensitivity or resistance of cells associated
 CC with a disease state; and (3) identifying polynucleotides and
 CC polypeptides that predict compound sensitivity or resistance of cells
 CC associated with a disease state, comprising subjecting the plurality of
 CC cell lines to one or more compounds, analysing the expression pattern of
 CC a microarray of polynucleotides or polypeptides, and selecting
 CC polynucleotides or polypeptides that predict the sensitivity or
 CC resistance of cells associated with a disease state by using the
 CC expression pattern of the microarray. The polynucleotides and
 CC polypeptides have cytostatic activities, and can be used in gene therapy.
 CC The polynucleotides and polypeptides are useful in predicting the
 CC activity of compounds that interact with protein tyrosine kinases and/or
 CC protein tyrosine kinase pathways. These may be used in determining drug
 CC sensitivity in patients to allow the development of individualized
 CC genetic profiles which aid in treating diseases and disorders (e.g.
 CC cancer) based on patient response at a molecular level. The present
 CC sequence is used in the exemplification of the present invention.
 XX
 SQ Sequence 2691 BP; 600 A; 780 C; 831 G; 480 T; 0 U; 0 Other;
 Query Match 100.0%; Score 215; DB 10; Length 2691;
 Best Local Similarity 100.0%; Pred. No. 1.e-54; Indels 0; Gaps 0;
 Matches 215; Conservativeness 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 ATAACGGCTAGCTGAGGAGCTGGACAGTCCTACACTTTCTGAGAGTGACTCC 60
 Db 274 ATAACGGCTAGCTGAGGAGCTGGACAGTCCTACACTTTCTGAGAGTGACTCC 333
 Qy 61 GTGTGTCCTAACGGCTCCAGGCCAGGCTGCGAGCTGGACAGTCCTACACTTTCTGAGAGTGACTCC 120
 Db 334 GTGTGTCCTAACGGCTCCAGGCCAGGCTGCGAGCTGGACAGTCCTACACTTTCTGAGAGTGACTCC 393
 Qy 121 CGGGCTCCGGAGGAGCGAGCTCTCTGGGATCACTGTTCCGGTTCAGGCCCAA 180
 Db 394 CGGGCTCCGGAGGAGCGAGCTCTCTGGGATCACTGTTCCGGTTCAGGCCCAA 453
 Qy 181 TCTCAGAGCCGAGCCGAGAGAGACCGC 215
 Db 454 TCTCAGAGCCGAGCCGAGAGAGACCGC 488
 XX
 Sequence 2732 BP; 608 A; 787 C; 840 G; 497 T; 0 U; 0 Other;
 Query Match 99.5%; Score 214; DB 10; Length 2732;
 Best Local Similarity 100.0%; Pred. No. 2.3e-54; Indels 0; Gaps 0;
 Matches 214; Conservativeness 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 ATAACGGCTAGCTGAGGAGCTGGACAGTCCTACACTTTCTGAGAGTGACTCC 60
 Db 274 ATAACGGCTAGCTGAGGAGCTGGACAGTCCTACACTTTCTGAGAGTGACTCC 333
 Qy 61 GTGTGTCCTAACGGCTCCAGGCCAGGCTGCGAGCTGGACAGTCCTACACTTTCTGAGAGTGACTCC 120
 Db 334 GTGTGTCCTAACGGCTCCAGGCCAGGCTGCGAGCTGGACAGTCCTACACTTTCTGAGAGTGACTCC 393
 Qy 121 CGGGCTCCGGAGGAGCGAGCTCTCTGGGATCACTGTTCCGGTTCAGGCCCAA 180
 Db 394 CGGGCTCCGGAGGAGCGAGCTCTCTGGGATCACTGTTCCGGTTCAGGCCCAA 453
 Qy 181 TCTCAGAGCCGAGCCGAGAGAGACCGC 215
 Db 394 CGGGCTCCGGAGGAGCGAGCTCTCTGGGATCACTGTTCCGGTTCAGGCCCAA 453
 Qy 181 TCTCAGAGCCGAGCCGAGAGAGACCGC 214

Db 454 TCTCAGAGCCGAGCCGACAGAGAGCAGGAACCG 487
 CC preventing or treating cancer. The composition is also used for preparing
 CC a medicament for the therapeutic treatment or diagnostic detection of a
 CC cell proliferative disorder or cancer. The present sequence represents a
 CC human TAT cDNA sequence from the present invention.
 XX Sequence 2767 BP; 621 A; 808 C; 854 G; 484 T; 0 U; 0 Other;
 XX
 RESULT 7
 ADQ87261
 ID ADQ87261 standard; cDNA; 2767 BP.
 AC ADQ87261;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE Human tumour-associated antigenic target (TAT) cDNA sequence #4138.
 XX human; tumour-associated antigenic target; TAT; cytostatic; gene therapy;
 KW cancer; cell proliferative disorder; gene; ss.
 OS Homo sapiens.
 XX WO2004060270-A2.
 XX
 PD 22-JUL-2004.
 XX
 PR 15-OCT-2003; 2003WO-US029126.
 XX
 PR 18-OCT-2002; 2002US-0418988P.
 XX
 PA (GETH) GENENTECH INC.
 PA (WUTD/) WU T D.
 PA (ZHOU/) ZHOU Y.
 XX
 PI Wu TD, Zhou Y;
 XX
 DR WPI; 2004-534300/51.
 XX
 PT New nucleic acid molecule and encoded polypeptide, for diagnosing,
 PT preventing or treating cell proliferative disorders such as cancer.
 XX
 PS Claim 1; SEQ ID NO 4138; 5504pp; English.
 XX
 CC The present invention describes an isolated tumour-associated antigenic
 CC target (TAT) nucleic acid comprising: (a) any of 4622 nucleotide
 CC sequences (see SEQ ID NO:1 to 4622); (b) the full-length coding region of
 CC (a); (c) the complement of (a) or (b); (d) a sequence that has 80%
 CC sequence identity to (a)-(c); or (e) a sequence that hybridises to (a)-(c).
 CC Also described: (1) an expression vector comprising the above
 CC nucleic acid; (2) a host cell comprising the above expression vector; (3)
 CC a process for producing a polypeptide; (4) an isolated polypeptide
 comprising: (a) an amino acid sequence encoded by any of the above
 CC nucleotide sequences; (b) an amino acid sequence encoded by the full-
 CC length coding region of the above nucleotide sequences; or (c) a sequence
 CC having at least 80% identical to (a) or (b); (5) a chimeric polypeptide
 CC comprising the above polypeptide fused to a heterologous polypeptide; (6)
 CC an isolated antibody that binds to the above polypeptide; (7) a process
 CC for producing the antibody; (8) an isolated oligopeptide that binds to
 CC the above polypeptide; (9) a tumour-associated antigenic target (TAT)
 CC binding organic molecule that binds to the above polypeptide; (10) a
 CC antibody, oligopeptide or TAT binding organic molecule, in combination
 CC with a carrier; (11) an article of manufacture comprising a container and
 CC the composition of matter contained within the container; (12) methods of
 CC inhibiting the growth of a cell that expresses the above protein, where
 CC the growth of the cell is at least in part dependent upon a growth
 CC potentiating effect of the above protein; (13) a method of
 CC therapeutically treating a mammal having a cancerous tumour comprising
 CC cells that express the above protein; (14) a method of determining the
 CC presence of a protein in a sample suspected of containing the protein
 CC described above; (15) methods of diagnosing the presence of a tumour in a
 CC mammal; (16) a method for treating or preventing a cell proliferative
 CC disorder associated with increased expression or activity of the above
 CC protein; and (17) a method of binding an antibody, oligopeptide or
 CC organic molecule to a cell that expresses the protein described above.
 CC The TAT sequences have cytostatic activities, and can be used in gene
 therapy. The composition and methods are useful for diagnosing,
 CC

RESULT 8
 ADQ84979
 ID ADQ84979 standard; cDNA; 2767 BP.
 XX
 AC ADQ84979;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE Human tumour-associated antigenic target (TAT) cDNA sequence #1793.
 XX human; tumour-associated antigenic target; TAT; cytostatic; gene therapy;
 KW cancer; cell proliferative disorder; gene; ss.
 OS Homo sapiens.
 XX WO2004060270-A2.
 XX
 PD 22-JUL-2004.
 XX
 PR 15-OCT-2003; 2003WO-US029126.
 XX
 PR 18-OCT-2002; 2002US-0418988P.
 XX
 PA (GETH) GENENTECH INC.
 PA (WUTD/) WU T D.
 PA (ZHOU/) ZHOU Y.
 XX
 PI Wu TD, Zhou Y;
 XX
 DR WPI; 2004-534300/51.
 XX
 PT New nucleic acid molecule and encoded polypeptide, for diagnosing,
 PT preventing or treating cell proliferative disorders such as cancer.
 XX
 PS Claim 1; SEQ ID NO 1793; 5504pp; English.
 XX
 CC The present invention describes an isolated tumour-associated antigenic
 CC target (TAT) nucleic acid comprising: (a) any of 4622 nucleotide
 CC sequences (see SEQ ID NO:1 to 4622); (b) the full-length coding region of
 CC (a); (c) the complement of (a) or (b); (d) a sequence that has 80%
 CC sequence identity to (a)-(c); or (e) a sequence that hybridises to (a)-(c).
 CC Also described: (1) an expression vector comprising the above
 CC nucleic acid; (2) a host cell comprising the above expression vector; (3)
 CC a process for producing a polypeptide; (4) an isolated polypeptide
 comprising: (a) an amino acid sequence encoded by any of the above

CC nucleotide sequences; (b) an amino acid sequence encoded by the full-length coding region of the above nucleotide sequences; or (c) a sequence having at least 80% identical to (a) or (b); (5) a chimeric polypeptide comprising the above polypeptide fused to a heterologous polypeptide; (6) an isolated antibody that binds to the above polypeptide; (7) a process for producing the antibody; (8) an isolated oligopeptide that binds to the above polypeptide; (9) a tumour-associated antigenic target (TAT) binding organic molecule that binds to the above polypeptide; (10) a composition of matter comprising the above (chimeric) polypeptide, antibody, oligopeptide or TAT binding organic molecule, in combination with a carrier; (11) an article of manufacture comprising a container and the composition of matter contained within the container; (12) methods of inhibiting the growth of a cell that expresses the above protein, where the growth of the cell is at least in part dependent upon a growth potentiating effect of the above protein; (13) a method of determining the presence of a protein in a sample suspected of containing the protein described above; (14) methods of diagnosing the presence of a tumour in a mammal; (16) a method for treating or preventing a cell proliferative disorder associated with increased expression or activity of the above protein; and (17) a method of binding an antibody, oligopeptide or organic molecule to a cell that expresses the protein described above. The TAT sequences have cytostatic activities, and can be used in gene therapy. The composition and methods are useful for diagnosing, preventing or treating cancer. The composition is also used for preparing a medicament for the therapeutic treatment or diagnostic detection of a cell proliferative disorder or cancer. The present sequence represents a human TAT cDNA sequence from the present invention.

SQ Sequence 2767 BP; 621 A; 809 C; 853 G; 484 T; 0 U; 0 Other;

Query Match 99.5%; Score 214; DB 12; Length 2767;

Best Local Similarity 100.0%; Pred. No. 2.3e-54;

Matches 214; Conservativeness 0; Mismatches 0; Indels 0; Gaps 0;

CC 1 ATAACGGCTAGCTGAGAGCTCGGAGACTGCTGAGACTTGTGAGAGTGTCTCC 60

Db 362 ATAACGGCTAGCTGAGAGCTCGGAGACTGCTGAGACTTGTGAGAGTGTCTCC 421

CC 61 GTTGTCCTCAAGGCTTCCAGGAGGAGCTGCTGGGGCTGAGAGTGTCTCC 120

Qy 422 GTGTGCCAAAGGTCTCCAGGAGGAGCTGCTGGGGCTGAGAGTGTCTCC 481

Db 121 CGGGCGTCCGGAGGAGGAGGAGCTCTCGGGATCCAGTGTCCGGTTCCGGCCCAA 180

Qy 482 CGGGCGTCCGGAGGAGGAGGAGCTCTCGGGATCCAGTGTCCGGTTCCGGCCCAA 541

Qy 181 TCTCAGAGCCGAGCCGAGAGAGAGAGAGACCG 214

Db 542 TCTCAGAGCCGAGCCGAGAGAGAGAGACCG 575

RESULT 9

ID ADQ83802

ID ADQ83802 standard; cDNA; 2767 BP.

XX ADQ83802;

AC

XX

DT 07-OCT-2004 (first entry)

XX Human tumour-associated antigenic target (TAT) cDNA sequence #616.

XX human; tumour-associated antigenic target; TAT; cytostatic; gene therapy;

XX cancer; cell proliferative disorder; gene; ss.

OS Homo sapiens.

XX WO2004060270-A2.

XX 22-JUL-2004.

XX 15-OCT-2003; 2003WO-US029126.

XX PR 18-OCT-2002; 2002US-041898B.

XX PA (GETH) GENENTECH INC.

PA (WUDI) WU T D.

PA (ZHOU) ZHOU Y.

XX PI Wu TD, Zhou Y;

XX DR WPI; 2004-534300/51.

PT New nucleic acid molecule and encoded polypeptide, for diagnosing, preventing or treating cell proliferative disorders such as cancer.

XX PS

Claim 1; SEQ ID NO 616; 5504pp; English.

CC The present invention describes an isolated tumour-associated antigenic target (TAT) nucleic acid comprising: (a) any of 4622 nucleotide sequences (see SEQ ID NO:1 to 4622); (b) the full-length coding region of (a); (c) the complement of (a) or (b); (d) a sequence that has 80% sequence identity to (a)-(c); or (e) a sequence that hybridises to (a)-(c). Also described: (1) an expression vector comprising the above nucleic acid; (2) a host cell comprising the above expression vector; (3) a process for producing a polypeptide; (4) an isolated polypeptide comprising: (a) an amino acid sequence encoded by the full-length coding region of the above nucleotide sequence; or (c) a sequence comprising the above polypeptide fused to a heterologous polypeptide; (6) an isolated antibody that binds to the above polypeptide; (7) a process for producing the antibody; (8) an isolated oligopeptide that binds to the above polypeptide; (9) a tumour-associated antigenic target (TAT) binding organic molecule that binds to the above (chimeric) polypeptide, composition of matter comprising the above organic molecule, in combination with a carrier; (11) an article of manufacture comprising a container and the composition of matter contained within the container; (12) methods of inhibiting the growth of a cell that expresses the above protein, where the growth of the cell is at least in part dependent upon a growth potentiating effect of the above protein; (13) a method of determining the presence of a protein in a sample suspected of containing the protein described above; (14) methods of diagnosing the presence of a tumour in a mammal; (16) a method for treating or preventing a cell proliferative disorder associated with increased expression or activity of the above protein; and (17) a method of binding an antibody, oligopeptide or organic molecule to a cell that expresses the protein described above. The TAT sequences have cytostatic activities, and can be used in gene therapy. The composition and methods are useful for diagnosing, preventing or treating cancer. The composition is also used for preparing a medicament for the therapeutic treatment or diagnostic detection of a cell proliferative disorder or cancer. The present sequence represents a human TAT cDNA sequence from the present invention.

XX SQ Sequence 2767 BP; 621 A; 808 C; 854 G; 484 T; 0 U; 0 Other;

Query Match 99.5%; Score 214; DB 13; Length 2767;

Best Local Similarity 100.0%; Pred. No. 2.3e-54;

Matches 214; Conservativeness 0; Mismatches 0; Indels 0; Gaps 0;

CC 1 ATAACGGCTAGCTGAGAGCTCGGAGACTGCTGAGACTTGTGAGAGTGTCTCC 60

Db 362 ATAACGGCTAGCTGAGAGCTCGGAGACTGCTGAGACTTGTGAGAGTGTCTCC 421

CC 61 GTTGTCCTCAAGGCTTCCAGGAGGAGCTGCTGGGGCTGAGAGTGTCTCC 120

Db 422 GTGTGCCAAAGGTCTCCAGGAGGAGCTGCTGGGGCTGAGAGTGTCTCC 481

Qy 121 CGGGCGTCCGGAGGAGGAGGAGCTCTCGGGATCCAGTGTCCGGTTCCGGCCCAA 180

Qy 482 CGGGCGTCCGGAGGAGGAGGAGCTCTCGGGATCCAGTGTCCGGTTCCGGCCCAA 541

QY 181 TCTCAGAGCCGAGCCAGAGGAGGAGACCG 214
 Db 542 TCTCAGAGCCAGCCAGAGGAGGAGACCG 575

RESULT 10
 ADS8905
 ID ADS8905 standard; DNA; 5387 BP.
 XX
 AC ADSR9095;
 XX
 DT 18-NOV-2004 (first entry)
 XX
 DE Human HSPA1A gene SEQ ID NO:111.
 XX
 KW ds; gene; human; cell proliferative disorder; breast; methylation;
 KW cytotoxic; gene therapy; single nucleotide polymorphism; SNP.
 OS Homo sapiens.
 XX
 PN WO2004035803-A2.
 XX
 PD 29-APR-2004.
 XX
 PR 01-OCT-2003; 2003WO-EP010881.
 XX
 PR 01-OCT-2002; 2002DE-01045779.
 PR 07-JUN-2003; 2003DE-0100096.
 PR 17-APR-2003; 2003DE-01017955.
 XX
 PA (EPIC-) ERGENOMICS AG.
 XX
 PI Foekens J, Harbeck N, Koenig T, Maier S, Martens J, Model F,
 PI Nimmerich I, Rujan T, Schmitt A, Schmitt M, Look MP, Marx A;
 DR WPI; 2004-348468/32.

XX
 PT Predicting responsiveness of a subject with breast cell proliferative
 PT disorder, useful for treating or differentiating breast cell
 PT proliferative disorders comprises analyzing methylation pattern of a
 PT genomic DNA from the subject.
 XX
 PS Example 2; SEQ ID NO 111; 104pp; English.

XX
 CC The invention relates to a novel method for predicting the responsiveness
 CC of a subject with a cell proliferative disorder of the breast tissues to
 CC a therapy comprising analysing the methylation pattern of a target
 CC nucleic acid by contacting at least one of the target nucleic acids in a
 CC biological sample obtained from the subject prior to or during treatment.
 CC The method of the invention has cytotoxic activity, and may have a use
 CC in gene therapy. The set of oligonucleotides comprising at least two of
 CC the oligomers are useful for detecting the cytosine methylation state
 CC and/or single nucleotide polymorphisms (SNPs) within the sequences. The
 CC methods, nucleic acid, oligonucleotide, and kit are useful for the
 CC treatment, characterisation, classification and/or differentiation, of
 CC breast cell proliferative disorders. The method is also useful for
 CC predicting the responsiveness of a subject with a cell proliferative
 CC disorder of the breast tissues to a therapy. The present sequence is used
 CC in the exemplification of the invention.

SQ Sequence 5387 BP; 1291 A; 1506 C; 1471 G; 1119 T; 0 U; 0 Other;

Query Match 99.5%; Score 214; DB 13; Length 5387;
 Best Local Similarity 100.0%; Pred. No. 2.7e-54; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAACCGCTTACCTGAGGAGCTGCTGAGCTTACCTTTCGAGGTGACTCC 60
 Db 1982 ATAACGGCTTACCTGAGGAGCTGCTGAGCTTACCTTTCGAGGTGACTCC 2041

QY 61 GTGTGCCAAGCTTCCAGAGGACCTGCGGCTGAGGACCCGGGGTCTGAGTT 120
 Db 2042 GTGTGCCAAGCTTCCAGAGGACCTGCGGCTGAGGACCCGGGGTCTGAGTT 2101

RESULT 11
 ADA45212
 ID ADA45212 standard; DNA; 549 BP.
 XX
 AC ADA45212;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human hsp70 gene 5' promoter region.
 XX
 KW gene; ds; human; tumour mass; cancer; bone marrow;
 KW endothelial cell precursor; ECP; cytotoxic;
 KW tumour angiogenesis inhibitor; gene therapy; cell therapy; angiogenesis;
 KW hsp70; promoter.
 XX
 OS Homo sapiens.
 XX
 PN WO2003061591-A2.
 XX
 PR 31-JUL-2003.
 XX
 PR 22-JAN-2003; 2003WO-US001827.
 XX
 PR 22-JAN-2002; 2002US-0349345P.
 XX
 PA (ADCB-) ADVANCED CELL TECHNOLOGY INC.
 XX
 PR West MD;
 XX
 DR WPI; 2003-598707/56.

XX
 PT Decreasing tumor mass in a patient comprises grafting genetically
 PT modified endothelial cell precursors into the patient.

XX
 PS Example 3; Fig 1; 34pp; English.

XX
 CC The invention relates to a novel method for decreasing tumour mass in a
 CC cancer patient. The method comprises ablating bone marrow from the
 CC patient and grafting endothelial cell precursors (ECPs), or their
 CC precursors, into the patient such that a decrease in tumour mass results,
 CC where the ECPs or their precursors are genetically modified to mediate a
 CC decrease in tumour mass. The method of the invention has cytotoxic
 CC activity. A polynucleotide of the invention acts as a tumour angiogenesis
 CC inhibitor, and may have a use in gene therapy and cell therapy.
 CC Genetically modified endothelial cell precursors are useful for
 CC decreasing tumour mass in a cancer patient. This is particularly useful
 CC for inhibiting and/or disrupting angiogenesis of the tumours, and
 CC consequently inhibiting tumour growth and killing tumour cells. The
 CC present sequence represents the 5' promoter region of the human hsp70
 CC gene.

SQ Sequence 549 BP; 110 A; 174 C; 167 G; 98 T; 0 U; 0 Other;

Query Match 99.3%; Score 213.4; DB 9; Length 549;
 Best Local Similarity 99.5%; Pred. No. 2.4e-54; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAACGGCTTACCTGAGGAGCTGCTGAGCTTACCTTTCGAGGTGACTCC 60
 Db 269 ATAACGGCTTACCTGAGGAGCTGCTGAGCTTACCTTTCGAGGTGACTCC 328

QY 61 GTGTGCCAAGCTTCCAGAGGACCTGCGGCTGAGGACCCGGGGTCTGAGTT 120
 Db 2042 GTGTGCCAAGCTTCCAGAGGACCTGCGGCTGAGGACCCGGGGTCTGAGTT 2101

SQ	Sequence 213 BP; 40 A; 71 C; 63 G; 39 T; 0 U; 0 Other;	CC	of Hsp72 or JNK phosphatase activity. The compounds identified as inhibitors of Hsp72 or JNK phosphatase activity are useful for inhibiting the proliferation of cells. Modulation of the activity of the JNK phosphatase or Hsp72 is used to treat a proliferative disorder such as
Query Match	99.1%; Score 213; DB 12; Length 213;	CC	cancers (e.g., leukaemia, lymphoma, solid tumours such as sarcomas and carcinomas, breast cancer, prostate cancer). The compounds that inhibit
Best Local Similarity	100.0%; Pred. No. 2.6e-54; Mismatches 0; Indels 0; Gaps 0;	CC	Hsp72 activity can also be administered to treat premalignant conditions and to prevent progression to a neoplastic or malignant state. The
Matches	213; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	CC	compounds that inhibit Hsp72 function are administered to a patient having a disease or disorder mediated by an increase of Hsp72 expression or activity relative to normal levels. The present sequence represents
QY	3 AACGGCTAGCTTGAGGAGCTGCTGGAGACAGTCACCTTTCAGAGTGACTCCGT 62	CC	CC having a disease or disorder mediated by an increase of Hsp72 expression or activity relative to normal levels. The present sequence represents
Db	1 AACGGCTAGCTTGAGGAGCTGCTGGAGACAGTCACCTTTCAGAGTGACTCCGT 60	CC	CC a DNA encoding human Hsp72 used in the exemplifications of the invention
QY	63 TCTCCCAAGGCTTCCAGAGGAGCTGCTGGCTSGAGGACCGGGGGTGGAGTTCC 122	CC	XX Sequence 2700 BP; 601 A; 780 C; 834 G; 485 T; 0 U; 0 Other;
Db	61 TGTCCCAAGGCTTCCAGAGGAGCTGCTGGCTSGAGGACCGGGGGTGGAGTTCC 120	CC	XX Sequence 2700 BP; 601 A; 780 C; 834 G; 485 T; 0 U; 0 Other;
QY	123 GAGGTGGAGGAGGAGCTCTGGGATTCAGTGTGGTTTCAGCCCCAATC 182	CC	Query Match 98.8%; Score 212.4; DB 3; Length 2700;
Db	121 GCGTCGGAGGAGGAGCTCTGGGATTCAGTGTGGTTTCAGCCCCAATC 180	CC	Best Local Similarity 99.5%; Pred. No. 6.9e-54; Mismatches 1; Indels 0; Gaps 0;
QY	183 TCTAGGGCGAGCAGGAGGAGGAGGACCC 215	CC	Db 274 ATAACGCTAGCCTGAGGAGCTGCTGGAGACAGTCACCTTTCAGAGTGACTCC 333
Db	181 TCTAGGGCGAGCAGGAGGAGGACCC 213	CC	QY 61 GTGTGCCAAGGCTTCCAGAGGAGCTGCTGGCTGAGGACCG 60
RESULT 14		CC	Db 334 GTGTGCCAAGGCTTCCAGAGGAGCTGCTGGCTGAGGACCG 393
AAA97541		CC	AC AAA97541; 29-JAN-2001 (first entry)
ID	AAA97541 standard; cDNA; 2700 BP.	CC	QY 121 CCGGGCGCCGAGGAGGAGCTCTTCAGGGATCCAGTGTGGTTTCAGCCCCAA 180
XX		CC	Db 394 CCGGGCGCCGAGGAGGAGCTCTTCAGGGATCCAGTGTGGTTTCAGCCCCAA 453
AC		CC	QY 181 TCTCAGGCCAGGCCAGAGAGCAGGGACCG 214
XX		CC	Db 454 TCTCAGGCCAGGCCAGAGAGCAGGGACCG 487
DT		CC	RESULT 15
XX		CC	ADM02338
DE	Human Hsp72 (heat shock protein 72) cDNA.	CC	ID ADM02338 standard; cDNA; 1903 BP.
XX		CC	XX
KW	Human Hsp72; heat shock protein 72; chromosome 6p21.3; Hsp72 inhibitor; expression modulator; JNK phosphatase inhibitor; antiproliferative; drug screening; cancer; leukaemia; lymphoma; solid tumour; sarcoma; carcinoma; breast cancer; prostate cancer; premalignant condition; ss.	CC	AC ADM02338;
XX		CC	XX
DE	Human Hsp72 (heat shock protein 72) cDNA.	CC	DT 20-MAY-2004 (first entry)
XX		CC	XX
PP	17-MAR-2000; 2000WO-US007350.	CC	DE Human cDNA of the invention SEQ ID NO:1023.
XX		CC	XX
PR	18-MAR-1999; 99US-0125046P.	CC	SS; gene; human; gene therapy; diagnostic marker; pharmaceutical.
XX		CC	OS Homo sapiens.
PA	(PHYL-) PHYLOGENY INC.	CC	XX
XX		CC	EP1347046-A1.
PI	Volloch VZ, Sherman M;	CC	XX
XX		CC	PD 24-SEP-2003.
DR	WPI; 2000-647055/62.	CC	XX
DR	P-PSDB; AAB23252.	CC	PP 12-APR-2002; 2002EP-00008400.
XX		CC	XX
PT	Identifying compounds that inhibit proliferation of cells and capable of modulating the expression of heat shock protein 72 gene and/or activity of Hsp72 useful for treating cancers such as leukemia, lymphoma.	CC	PR 22-MAR-2002; 2002JP-00137785.
PT		CC	XX
PS	Example; Fig 16A; 77pp; English.	CC	(REAS-) RES ASSOC BIOTECHNOLOGY.
XX		CC	XX
CC	The invention relates to a novel method of identifying compounds that inhibit proliferation of cells comprising contacting a test compound with a cell which overexpresses Hsp72 (heat shock protein 72), and determining if the test compound inhibits activity or expression of Hsp72. Optionally, Hsp72 is contacted with the test compound under optimum conditions to allow the two components to interact and bind, forming a complex which is detected. The invention also relates to a method of identifying compounds that inhibit Hsp72-mediated JNK phosphatase activation, comprising contacting a test compound with a cell which expresses Hsp72, exposing the cell to a heat induced stress and determining if the compound inhibits JNK phosphatase activity. The invention additionally encompasses compositions comprising an inhibitor	CC	PI Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S; PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I; PI Seki N, Yoshikawa T, Otsuka M, Nagahara K, Masuho Y; XX DR WPI; 2003-723558/69.
CC		CC	DR P-PSDB; AAB04781.
CC		CC	XX
CC	New Polynucleotides and Polypeptides are useful in gene therapy, for developing a diagnostic marker or medicines for regulating their expression and activity, or as a target of gene therapy.	CC	XX
CC		CC	PS Claim 1; SEQ ID NO 1023; 305pp; English.
CC		CC	XX

CC The invention relates to a novel human polynucleotide and the encoded
 CC polypeptide. A polynucleotide of the invention may have a use in gene
 CC therapy. An oligonucleotide of the invention ADM0202-ADM0673 is useful
 CC as a primer for synthesizing the polynucleotide or as a probe for
 detecting the polynucleotide. The polynucleotides ADM01316-ADM03758 are
 CC useful in gene therapy, for developing a diagnostic marker or medicines
 CC for regulating their expression and activity, or as a target of gene
 CC therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides
 CC are useful as pharmaceutical agents. The present sequence represents a
 CC cDNA sequence of the invention.

XX Sequence 1903 BP; 425 A; 531 C; 590 G; 357 T; 0 U; 0 other;

Query Match 97.9%; Score 210.4; DB 11; Length 1903;

Best Local Similarity 99.5%; Pred. No. 2.6e-53; Matches 211; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy	3	AACGGCTAGCCCTGAGGAGCTGCTGGACAGTCACACTTTCGAGAGTGACTCCGT	62
Db	1	AACGGCTAGCCCTGAGGAGCTGCTGGACAGTCACACTTTCGAGAGTGACTCCGT	60
Qy	63	TGTCCCAAGGCTTCCAGAGGAGCTGCTGGCTGAGGACCCGGCGTGAGTTCC	122
Db	61	TGTCCCAAGGCTTCCAGAGGAGCTGCTGGCTGAGGACCCGGCGTGAGTTCC	120
Qy	123	GCGTCCGGAGGACCGAGCTCTCTGGCATCCAGTGTGTTCCACCCCCAATC	182
Db	121	GGGTCGGAGGACCGAGCTCTCTGGCATCCAGTGTGTTCCACCCCCAATC	180
Qy	183	TCAGAGCGGAGGACGAGGACGAGGACCG 214	
Db	181	TCAGAGCGGAGGACGAGGACGAGGACCG 212	

Search completed: February 11, 2005, 08:17:28
 Job time : 224 sec

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 11, 2005, 07:52:23 ; Search time 87 Seconds
(without alignments)

4043.672 Million cell updates/sec

Title: US-09-936-506-1

Perfect score: 215

Sequence: 1 ataaacggctatggctggagag.....gacagagagcggaaacgc 215

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 2405568

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents NA:
1: /cgnd_6/prodata/1/ina/5A_COMB.seq: *
2: /cgnd_6/prodata/1/ina/5B_COMB.seq: *
3: /cgnd_6/prodata/1/ina/6A_COMB.seq: *
4: /cgnd_6/prodata/1/ina/6B_COMB.seq: *
5: /cgnd_6/prodata/1/ina/PCITS_COMB.seq: *
6: /cgnd_6/prodata/1/ina/backfile1.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	215	100.0	533	1	US-07-975-719-2	Sequence 2, Appli
2	215	100.0	533	1	US-08-599-825-2	Sequence 2, Appli
3	215	100.0	533	2	US-09-048-488-2	Sequence 1, Appli
4	215	100.0	2691	3	US-08-955-555A-1	Sequence 1, Appli
5	191.4	89.0	2412	4	US-09-919-039-144	Sequence 144, Appli
6	187.4	87.2	420	4	US-09-621-976-827	Sequence 827, Appli
7	156.8	72.9	2458	4	US-09-919-039-145	Sequence 145, Appli
8	99.2	46.1	1941	4	US-09-976-524-996	Sequence 996, Appli
9	36.6	17.0	750	1	US-07-975-719-1	Sequence 1, Appli
10	36.6	17.0	750	1	US-08-599-825-1	Sequence 1, Appli
11	36.6	17.0	750	2	US-09-048-488-1	Sequence 1, Appli
12	33.6	15.6	1074	4	US-09-252-991A-11809	Sequence 11809, A
13	33.6	15.6	1320	4	US-09-252-991A-11869	Sequence 11869, A
14	32.4	15.1	205	4	US-09-313-299A-6467	Sequence 6467, Appli
15	32.4	15.1	1728	4	US-09-902-540-4475	Sequence 4475, Appli
16	32.4	15.1	2812	4	US-09-902-540-1221	Sequence 1221, Appli
17	32.4	15.0	1938	3	US-08-902-540-1111	Sequence 1111, Appli
18	31.8	14.8	4722	3	US-08-979-698A-14	Sequence 14, Appli
19	31.8	14.8	4722	4	US-08-917-491-14	Sequence 14, Appli
20	31.8	14.8	4722	4	US-09-616-289-14	Sequence 17483, A
21	31.8	14.8	27825	4	US-09-949-016-17483	Sequence 5, Appli
22	31.5	14.7	1195	1	US-08-567-538-5	Sequence 5, Appli
23	31.6	14.7	1196	4	US-08-016-17339	Sequence 17339, A
24	31.4	14.6	601	4	US-09-949-016-17339	Sequence 12535, Appli
25	31.4	14.6	601	4	US-09-949-016-123356	Sequence 12536, Appli
26	31.4	14.6	601	4	US-09-949-016-123356	Sequence 11756, A
27	31.4	14.6	11752	4	US-09-949-016-11756	Sequence 11756, A

ALIGNMENTS

RESULT 1
US-07-975-719-2
; Sequence 2, Application US/07975719
; Patent No. 5521084
; GENERAL INFORMATION:
; APPLICANT: KOWALSKI, JACEK
; APPLICANT: GILBERT, SCOTT
; APPLICANT: ZAMB, TIMOTHY J.
; TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROBERTA L. ROBINS
; STREET: 635 BRYANT STREET
; CITY: PALO ALTO
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/975-719
; FILING DATE: 1992113
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: ROBINS, ROBERTA L.
; REGISTRATION NUMBER: 33,208
; REFERENCE/DOCKET NUMBER: 9001-0003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 327-3221
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 533 base pairs
; LENGTH: 533 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-07-975-719-2
Query Match 100 %; Score 215; DB 1; Length 533;
Best Local Similarity 100 %; Pred. No. 5.6e-5%; Indels 0; Gaps 0;
Matches 215; Conservative 0; Mismatches 0;
Qy 1 ATAACGGCTAGCTGAGGAGTGCAGCAGTCCACTACCTTTCAGAGTGTACTCC 60
Db 235 ATAACGGCTAGCTGAGGAGTGCAGCAGTCCACTACCTTTCAGAGTGTACTCC 294

RESULT 2
US-08-599-825-2
; Sequence 2, Application US/08599825
; Patent No. 5733745
GENERAL INFORMATION:
; APPLICANT: KOWALSKI, JACEK
; APPLICANT: GILBERT, SCOTT
; APPLICANT: ZAMB, TIMOTHY J.
TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
TITLE OF INVENTION: THEREOF
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROBERTA L. ROBINS
; STREET: 285 HAMILTON AVENUE, SUITE 200
; CITY: PALO ALTO
; STATE: CALIFORNIA
COUNTRY: UNITED STATES OF AMERICA
ZIP: 94301
COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patient in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/599, 825
; FILING DATE:
; CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
; NAME: ROBINS, ROBERTA L.
; REGISTRATION NUMBER: 33, 208
; REFERENCE/DOCKET NUMBER: 9001-0003. 01
TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 327-3400
; TELEFAX: (415) 327-3231
; INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
; LENGTH: 533 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: Single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-599-825-2

Query Match 100.0%: Score 215; DB 1; Length 533;
Best Local Similarity 100.0%; Pred. No. 5, 6e-57;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGGCTTAGGCTTCTGGAGGAGCTGCTGGAGCAGTCCACACTTTGAGAGTGACTCC 60
Db 235 ATAACGGCTTACGGCTTCCAGAGGACCTTGCGCTGAGGACACTTCTGAGAGTGACTCC 294
QY 61 GTTGTTCCCAAGGCTTCCAGAGGACCTTGCGCTGAGGACACTTCTGAGAGTGAGTT 120
Db 295 GTTGTGTTCCCAAGGCTTCCAGAGGACCTTGCGCTGAGGACACTTCTGAGAGTGAGTT 354
QY 121 CCGCGTCTGGAGGACCGAGCTTCTGGAGGACCTTGCGCTGAGGACACTTCTGAGAGTGAGTT 180
Db 355 CCGCGTCTGGAGGACCGAGCTTCTGGAGGACACTTCTGAGAGTGAGTT 414
QY 181 TCTCAGAGCGAGCGAGAGGACCGAGGACACCC 215
Db 415 TCTCAGAGCGAGCGAGAGGACCGAGGACACCC 449

RESULT 3
US-09-048-488-2
; Sequence 2, Application US/09048488
; Patent No. 5981224
GENERAL INFORMATION:
; APPLICANT: KOWALSKI, JACEK
; APPLICANT: GILBERT, SCOTT
; APPLICANT: ZAMB, TIMOTHY J.
TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
TITLE OF INVENTION: THEREOF
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROBERTA L. ROBINS
; STREET: 635 BRYANT STREET
; CITY: PALO ALTO
; STATE: CALIFORNIA
COUNTRY: UNITED STATES OF AMERICA
ZIP: 94301
COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patient in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/048, 488
; FILING DATE:
; CLASSIFICATION:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US/07/975, 719
; FILING DATE: 1992-11-13
ATTORNEY/AGENT INFORMATION:
; NAME: ROBINS, ROBERTA L.
; REGISTRATION NUMBER: 33, 208
; REFERENCE/DOCKET NUMBER: 9001-0003
TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 617-8999
; TELEFAX: (415) 327-3231
; INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
; LENGTH: 533 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: Single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-09-048-488-2

Query Match 100.0%: Score 215; DB 2; Length 533;
Best Local Similarity 100.0%; Pred. No. 5, 6e-57;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGGCTTAGGCTTCTGGAGGAGCTGCTGGAGCAGTCCACACTTTGAGAGTGACTCC 60
Db 235 ATAACGGCTTACGGCTTCCAGAGGACCTTGCGCTGAGGACACTTCTGAGAGTGACTCC 294
QY 61 GTTGTTCCCAAGGCTTCCAGAGGACCTTGCGCTGAGGACACTTCTGAGAGTGAGTT 120
Db 295 GTTGTGTTCCCAAGGCTTCCAGAGGACCTTGCGCTGAGGACACTTCTGAGAGTGAGTT 354
QY 121 CCGCGTCTGGAGGACCGAGCTTCTGGAGGACCTTGCGCTGAGGACACTTCTGAGAGTGAGTT 180
Db 355 CCGCGTCTGGAGGACCGAGCTTCTGGAGGACACTTCTGAGAGTGAGTT 414
QY 181 TCTCAGAGCGAGCGAGAGGACCGAGGACACCC 215
Db 415 TCTCAGAGCGAGCGAGAGGACCGAGGACACCC 449

```

; Sequence 1, Application US/08955565A-1
; Patient No. 6333388
; GENERAL INFORMATION:
; APPLICANT: Malkovsky, Miroslav
; TITLE OF INVENTION: Immune Response Enhancer Therapy
; FILE REFERENCE: WARF-0325
; CURRENT APPLICATION NUMBER: US/08/955, 565A
; CURRENT FILING DATE: 1997-10-17
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1
; LENGTH: 2691
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-08-955-565A-1

Query Match 100.0%; Score 215; DB 3; Length 2691;
Best Local Similarity 100.0%; Pred. No. 8.7e-57; Mismatches 0; Indels 0; Gaps 0;
Matches 215; Conservative 0; Pairs 0; Gaps 0;

QY 1 ATATACGGTAGCTGAGGAGCTCTGCGACAGTCCACCTACCTTTGAGAGTGACATCCC
Db 274 ATTAACGGTAGCTGAGGAGCTCTGCGACAGTCCACCTTTGAGAGTGACATCCC 333
OY 61 GTTGTCCTCAAGGCTTCCAGAGGAGCTCTGCGACAGTCCACCTACCTTTGAGAGTGACATCCC 120
Db 334 GTTGTCCTCAAGGCTTCCAGAGGAGCTCTGCGACAGTCCACCTTTGAGAGTGACATCCC 60
OY 121 CGCGGTCTGGAGAGGACGAGCTCTTCGGGATCCAGTGGTTCCAGGGCAA 180
Db 394 CGCGGTCTGGAGAGGACGAGCTCTTCGGGATCCAGTGGTTCCAGGGCAA 453
OY 181 TCTCGAGGCCGAGCCGAGAGGAGGACGCC 215
Db 454 TCTCGAGGCCGAGCCGAGAGGAGGACGCC 488
RESULT 5
US-09-919-039-144
; Sequence 144, Application US/09919039
; Patent No. 6777066
; GENERAL INFORMATION:
; APPLICANT: Kase, Matthew R.
; TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES
; FILE REFERENCE: PA-0035 US
; CURRENT APPLICATION NUMBER: US/09/919, 039
; CURRENT FILING DATE: 2002-07-09
; PRIOR APPLICATION NUMBER: 60/222, 113
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 401
; SOFTWARE: PERL program
; SEQ ID NO 144
; LENGTH: 2412
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No. 6727066 242010.16
; US-09-919-039-144

Query Match 89.0%; Score 191.4; DB 4; Length 2412;
Best Local Similarity 99.0%; Pred. No. 1.7e-49; Mismatches 0; Indels 1; Gaps 1;
Matches 203; Conservative 0; Pairs 1; Gaps 1;

QY 11 GCGTGGAGGAGCTCTGGCACAGTCCTCCACCTACCTTTGAGAGTGACATCCC 70
Db 1 GCGTGGAGGAGCTCTGGCACAGTCCTCCACCTACCTTTGAGAGTGACATCCC 60
OY 71 GCGTGGAGGAGCTCTGGCACAGTCCTCCACCTACCTTTGAGAGTGACATCCC 129
Db 61 GCGTGGAGGAGCTCTGGCACAGTCCTCCACCTACCTTTGAGAGTGACATCCC 120
RESULT 6
US-09-621-976-827
; Sequence 827, Application US/09621976
; Patent No. 6633063
; GENERAL INFORMATION:
; APPLICANT: Milne, Edwards, J. B.
; APPLICANT: Jobert, S.
; APPLICANT: Giordano, J. Y.
; TITLE OF INVENTION: ESTs and Encoded Human Proteins
; FILE REFERENCE: GENEST-054PR2
; CURRENT APPLICATION NUMBER: US/09/621, 976
; CURRENT FILING DATE: 2000-07-21
; NUMBER OF SEQ ID NOS: 19335
; SOFTWARE: Patent.pn
; SEQ ID NO 827
; LENGTH: 420
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 218..418
; US-09-621-976-827

Query Match 87.2%; Score 187.4; DB 4; Length 420;
Best Local Similarity 97.7%; Pred. No. 1.8e-48; Mismatches 1; Indels 2; Gaps 2;
Matches 210; Conservative 1; Pairs 1; Gaps 2;

QY 1 ATTAACGGTAGCTGAGGAGCTCTGCGACAGTCCACCTACCTTTGAGAGTGACATCCC
Db 2 ATTAACGGTAGCTGAGGAGCTCTGCGACAGTCCACCTACCTTTGAGAGTGACATCCC 60
OY 61 GTTGTCCTCAAGGCTTCCAGAGGAGCTCTGCGACAGTCCACCTACCTTTGAGAGTGACATCCC 120
Db 62 GTTGTCCTCAAGGCTTCCAGAGGAGCTCTGCGACAGTCCACCTACCTTTGAGAGTGACATCCC 61
OY 121 CGCGGTCTGGAGAGGACGAGCTCTTCGGGATCCAGTGGTTCCAGGGCAA 179
Db 122 CGCGGTCTGGAGAGGACGAGCTCTTCGGGATCCAGTGGTTCCAGGGCAA 181
OY 180 ATCTCAGAGGCCAGCCACAGGAGGAGGAGCC 214
Db 182 ATCTCAGAGGCCAGCCACAGGAGGAGGAGCC 215
RESULT 7
US-09-919-039-145
; Sequence 145, Application US/09919039
; Patent No. 6727066
; GENERAL INFORMATION:
; APPLICANT: Kase, Matthew R.
; TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES
; FILE REFERENCE: PA-0035 US
; CURRENT APPLICATION NUMBER: US/09/919, 039
; CURRENT FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: 60/222, 113
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 401
; SOFTWARE: PERL Program
; SEQ ID NO 145
; LENGTH: 2453
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:

```

US-09-919-039-145

NAME/KEY: misc feature
OTHER INFORMATION: Incyte ID No. 6727066 1678695CB1

Query Match 72.9%; Score 156.8; DB 4; Length 2458;
Best Local Similarity 88.5%; Pred. No. 8.6e-39; Mismatches 0; Indels 0; Gaps 0;
Matches 170; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 11 GCCTGAGGAGCTGTGCGACAGTCACACTACCTTCGAGAGTGACTCCGTTCCCAA 70
Db 1 GCCTGAGGAGCTGTGCGACAGTCACACTACCTTCGAGAGTGACTCCGTTCCCAA 60

QY 71 GCGTTCGAGGAGGAAACCTGTGGGTGAGGTGAGGACCGCGGCGAGTTCCGGTCCGA 130
Db 61 GCGTTCGAGGAGGAAACCTGTGGGTGAGGTGAGGACCGCGGCGAGTTCCGGTCCGA 120

QY 131 GAGGGAGGCTCTCAGGGATCCAGTGTGCGTCTGAGAGTGACTCCGGTCCGA 190
Db 121 GAGGGAGTGTGCTGTGCGGATCCGGTCCGGTCCAGCCCCAGTCAGTCAGACG 180

QY 191 GAGGGAGCAGAG 202
Db 181 GAGCCACAGAG 192

RESULT 8
US-09-976-594-996
Sequence 996, Application US/09976594
Patent No. 6673549
GENERAL INFORMATION:
APPLICANT: Furness, Michael
APPLICANT: Buchbinder, Jenny
TITLE OF INVENTION: GENES EXPRESSED IN C3A LIVER CELL CULTURES TREATED WITH STEROIDS
FILE REFERENCE: PA-0041 US
CURRENT APPLICATION NUMBER: US/09/976,594
CURRENT FILING DATE: 2001-10-12
PRIORITY APPLICATION NUMBER: 60/240,409
PRIORITY FILING DATE: 2000-10-12
NUMBER OF SEQ ID NOS: 1143
SOFTWARE: PERL program
SEQ ID NO 996
LENGTH: 1941
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc feature
OTHER INFORMATION: Incyte ID No. 6673549 242010.60
US-09-976-594-996

Query Match 46.1%; Score 99.2; DB 4; Length 1941;
Best Local Similarity 89.2%; Pred. No. 5.3e-21; Mismatches 0; Indels 0; Gaps 0;
Matches 107; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 83 CGAACTGCGCGCTGAGGACCGCGCCGCGTCAAGTTCCGGGCTCGAAGGACGAGC 142
Db 1 CGAACTGCGCGCTGAGGACCGCGCCGCGTCAAGTTCCGGGCTCGAAGGACGAGC 60

QY 143 TCTCTCGGGATCCAGTGTCCGTTCCAGGCCCCAACTCAGAGCCGAGCCAGAG 202
Db 61 TCTCTCGGGATCCAGGATCCGGCGTTCCAGGCCCACTCTCAGAGCCGAGCCAGAG 120

RESULT 9
US-07-975-719-1
Sequence 1, Application US/07975719
Patent No. 5521084
GENERAL INFORMATION:
APPLICANT: KOWALSKI, JACEK
APPLICANT: GILBERT, SCOTT
APPLICANT: ZAMB, TIMOTHY J.
TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
TITLE OF INVENTION: THEREOF
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSE: ROBERTA L. ROBINS
STREET: 285 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CALIFORNIA
COUNTRY: UNITED STATES OF AMERICA
ZIP: 94301

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
FILING DATE: US/08/599,825
APPLICATION NUMBER: US/08/599,825
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: ROBINS, ROBERTA L.
REGISTRATION NUMBER: 33,208
REFERENCE/DOCKET NUMBER: 9001-0003
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 617-8999
TELEFAX: (415) 327-3231
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 750 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)

RESULT 10
US-08-599-825-1
Sequence 1, Application US/08599825
Patent No. 5733745
GENERAL INFORMATION:
APPLICANT: KOWALSKI, JACEK
APPLICANT: GILBERT, SCOTT
APPLICANT: ZAMB, TIMOTHY J.
TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
TITLE OF INVENTION: THEREOF
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSE: ROBERTA L. ROBINS
STREET: 285 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CALIFORNIA
COUNTRY: UNITED STATES OF AMERICA
ZIP: 94301

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
FILING DATE: US/08/599,825
APPLICATION NUMBER: US/08/599,825
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:

NAME: ROBINS, ROBERTA L.
 REGISTRATION NUMBER: 33, 203
 REFERENCE/DOCKET NUMBER: 9001-0003.01
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (415) 327-3400
 TELEFAX: (415) 327-3231
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 750 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 US-09-599-825-1

RESULT 11
 Query Match 17.0%; Score 36.6; DB 1; Length 750;
 Best Local Similarity 66.0%; Pred. No. 0.096; 34; Indels 1; Gaps 1;
 Matches 68; Conservative 0; Mismatches 34; Indels 1; Gaps 1;
 Qy 101 GGCACCCGGCGCTCGAGTTCCGGCGTCCGGAGGACGAGC-TCTCTCCGGATCCAG 159
 Db 552 GGCACCCGGCGCTCGAGTTCCGGCGTCCGGAGGACGCTCTGGTCCAGTCCTC 611
 Qy 160 TGTTCGTTTCAGCCCCAACTCTAGAGCCGAGCTTCGAGGAGCAG 202
 Db 612 TTCACCGATTTCAGGTTGAGCTTTCGGAGCCGAGAAG 654

RESULT 12
 US-09-252-991A-11809/c
 Sequence 11809, Application US/09252991A
 ; Patent No. 6551795
 GENERAL INFORMATION:
 APPLICANT: Marc J. Rubenfield et al.
 TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
 FILE REFERENCE: 107196.136
 CURRENT FILING DATE: 1999-02-18
 PRIOR APPLICATION NUMBER: US/09/252, 991A
 PRIOR FILING DATE: 1998-02-18
 PRIOR APPLICATION NUMBER: US 60/094, 190
 PRIOR FILING DATE: 1998-07-27
 NUMBER OF SEQ ID NOS: 33142
 SEQ ID NO 11809
 LENGTH: 1074
 TYPE: DNA
 ORGANISM: Pseudomonas aeruginosa
 US-09-252-991A-11809

Query Match 15.6%; Score 33.6; DB 4; Length 1074;
 Best Local Similarity 59.4%; Pred. No. 0.9; 39; Indels 0; Gaps 0;
 Matches 57; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
 Qy 82 GCGAACCTGCGGGCTCAGGACCCGGCGCTCGAGTTCCGGCGTCCGGAGGACGAG 141
 Db 828 GCGATCTGCGGGTTCAGGCCATGGGGCTCGAGTTCCGGCGTCCGGAGGACGAG 769
 Qy 142 CTCTCTCGCGATCCAGTGTGTCGGTCCAGCCCC 177
 Db 768 GAGATCGCCAGTCGGTGGCTTCAGCCCC 733

RESULT 13
 US-09-252-991A-11869/c
 Sequence 11869, Application US/09252991A
 ; Patent No. 6551795
 GENERAL INFORMATION:
 APPLICANT: Marc J. Rubenfield et al.
 TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
 FILE REFERENCE: 107196.136
 CURRENT APPLICATION NUMBER: US/09/252, 991A
 CURRENT FILING DATE: 1999-02-18
 PRIOR APPLICATION NUMBER: US 60/074, 788
 PRIOR FILING DATE: 1998-02-18
 PRIOR APPLICATION NUMBER: US 60/094, 190
 PRIOR FILING DATE: 1998-07-27
 NUMBER OF SEQ ID NOS: 33142
 SEQ ID NO 11869
 LENGTH: 1320
 TYPE: DNA
 ORGANISM: Pseudomonas aeruginosa
 US-09-252-991A-11869

Query Match 15.6%; Score 33.6; DB 4; Length 1320;
 Best Local Similarity 59.4%; Pred. No. 0.95; 34; Indels 1; Gaps 1;
 Matches 68; Conservative 0; Mismatches 34; Indels 1; Gaps 1;

RESULT 14
 US-09-313-294A-6467
 Sequence 6467, Application US/09313294A
 Patent No. 6476212
 GENERAL INFORMATION:
 APPLICANT: Lalgudi, Raghunath V.
 APPLICANT: Ito, Laura Y.
 APPLICANT: Sherman, Bradley K.
 TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM CORN EAR FILE REFERENCE: PL-0017 US
 CURRENT APPLICATION NUMBER: US/09/313, 294A
 CURRENT FILING DATE: 1999-05-14
 NUMBER OF SEQ ID NOS: 7600
 SOFTWARE: PERL Program
 SEQ ID NO: 6467
 LENGTH: 205
 TYPE: DNA
 ORGANISM: Zea mays
 FEATURE:
 NAME/KEY: misc_feature
 OTHER INFORMATION: Incyte ID No. 6476212 700351854H1
 NAME/KEY: unire
 LOCATION: 31, 178, 202-203
 OTHER INFORMATION: a, t, c, g, or other
 US-09-313-294A-6467

Query Match 15.1%; Score 32.4; DB 4; Length 205;
 Best Local Similarity 68.2%; Pred. No. 1.3; Matches 45; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
 Matches 45; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 149 CGGGATCCAGTGTCCAGCCCCAACTCTAGAGCGAGCGACAGAGCAG 208
 Db 80 CACGGAGCAAGATTCGTTGCTGCCATTAAACGGAGCGAGGAGGTCAAG 139
 QY 209 GRACCG 214
 Db 140 CRACGG 145

RESULT 15
 US-09-902-540-4475/c
 Sequence 4475, Application US/09902540
 Patent No. 6833447
 GENERAL INFORMATION:
 APPLICANT: Goldman, Barry S.
 APPLICANT: Hinkle, Gregory J.
 APPLICANT: Slater, Steven C.
 APPLICANT: Wieged, Roger C.
 TITLE OF INVENTION: *Myxococcus xanthus* Genome Sequences and Uses Thereof
 FILE REFERENCE: 38-101158491B
 CURRENT APPLICATION NUMBER: US/09/902, 540
 CURRENT FILING DATE: 2001-07-10
 PRIOR APPLICATION NUMBER: 60/217, 883
 PRIOR FILING DATE: 2000-07-10
 NUMBER OF SEQ ID NOS: 16825
 SEQ ID NO: 4475
 LENGTH: 1728
 TYPE: DNA
 ORGANISM: *Myxococcus xanthus*
 US-09-902-540-4475

Query Match 15.1%; Score 32.4; DB 4; Length 1728;

Matches 57; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
 Sequence 6467, Application US/09313294A
 Patent No. 6476212
 GENERAL INFORMATION:
 APPLICANT: Lalgudi, Raghunath V.
 APPLICANT: Ito, Laura Y.
 APPLICANT: Sherman, Bradley K.
 TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM CORN EAR FILE REFERENCE: PL-0017 US
 CURRENT APPLICATION NUMBER: US/09/313, 294A
 CURRENT FILING DATE: 1999-05-14
 NUMBER OF SEQ ID NOS: 7600
 SOFTWARE: PERL Program
 SEQ ID NO: 6467
 LENGTH: 205
 TYPE: DNA
 ORGANISM: Zea mays
 FEATURE:
 NAME/KEY: misc_feature
 OTHER INFORMATION: Incyte ID No. 6476212 700351854H1
 NAME/KEY: unire
 LOCATION: 31, 178, 202-203
 OTHER INFORMATION: a, t, c, g, or other
 US-09-313-294A-6467

Best Local Similarity 50.0%; Pred. No. 2.4;
 Matches 81; Conservative 0; Mismatches 81; Indels 0; Gaps 0;
 Sequence 1628, Application US/09313294A
 Patent No. 6476212
 GENERAL INFORMATION:
 APPLICANT: Lalgudi, Raghunath V.
 APPLICANT: Ito, Laura Y.
 APPLICANT: Sherman, Bradley K.
 TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM CORN EAR FILE REFERENCE: PL-0017 US
 CURRENT APPLICATION NUMBER: US/09/313, 294A
 CURRENT FILING DATE: 1999-05-14
 NUMBER OF SEQ ID NOS: 7600
 SOFTWARE: PERL Program
 SEQ ID NO: 1628
 LENGTH: 205
 TYPE: DNA
 ORGANISM: Zea mays
 FEATURE:
 NAME/KEY: misc_feature
 OTHER INFORMATION: Incyte ID No. 6476212 700351854H1
 NAME/KEY: unire
 LOCATION: 31, 178, 202-203
 OTHER INFORMATION: a, t, c, g, or other
 US-09-313-294A-6467

Search completed: February 11, 2005, 09:04:16
 Job time : 89 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 11, 2005, 08:35:16 ; Search time 259 Seconds

{Without alignments)
4898.065 Million cell updates/sec

Title: US-09-936-506-1
Perfect score: 215
Sequence: 1 ataaacggcttagctggagag.....gacagagagcggaaaccgc 215
Scoring table: IDENTITY_NUC
Gapop 10^-0 , Gapext 1.0

Searched: 5378673 seqs, 2950229984 residues

Total number of hits satisfying chosen parameters: 10757346

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : Published Applications-NA:*

1: /cgnd_6/prodata/1/pubpna/us07_PUBCOMB.seq: *
2: /cgnd_6/prodata/1/pubpna/FCT_NEW_PUB.seq: *
3: /cgnd_6/prodata/1/pubpna/us06_PUBCOMB.seq: *
4: /cgnd_6/prodata/1/pubpna/us07_NEW_PUB.seq: *
5: /cgnd_6/prodata/1/pubpna/FCTUS_PUBCOMB.seq: *
6: /cgnd_6/prodata/1/pubpna/us08_PUBCOMB.seq: *
7: /cgnd_6/prodata/1/pubpna/us08_PUBCOMB.seq: *
8: /cgnd_6/prodata/1/pubpna/us09_PUBCOMB.seq: *
9: /cgnd_6/prodata/1/pubpna/us09_PUBCOMB.seq: *
10: /cgnd_6/prodata/1/pubpna/us09_PUBCOMB.seq: *
11: /cgnd_6/prodata/1/pubpna/us09_NEW_PUB.seq: *
12: /cgnd_6/prodata/1/pubpna/us09_NEW_PUB.seq: *
13: /cgnd_6/prodata/1/pubpna/us10_PUBCOMB.seq: *
14: /cgnd_6/prodata/1/pubpna/us10_PUBCOMB.seq: *
15: /cgnd_6/prodata/1/pubpna/us10_PUBCOMB.seq: *
16: /cgnd_6/prodata/1/pubpna/us10_PUBCOMB.seq: *
17: /cgnd_6/prodata/1/pubpna/us10_PUBCOMB.seq: *
18: /cgnd_6/prodata/1/pubpna/us10_PUBCOMB.seq: *
19: /cgnd_6/prodata/1/pubpna/us10_NEW_PUB.seq: *
20: /cgnd_6/prodata/1/pubpna/us11_NEW_PUB.seq: *
21: /cgnd_6/prodata/1/pubpna/us60_NEW_PUB.seq: *
22: /cgnd_6/prodata/1/pubpna/us60_PUBCOMB.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No. Score Query Match Length DB ID Description

US-10-335-053-291
RESULT 1
; Sequence 291, Application US/10335053
; Publication No. US20040241653A1
; GENERAL INFORMATION:
; APPLICANT: Quark Biotech, Inc.
; TITLE OF INVENTION: Methods for identifying marker genes for cancer
; CURRENT FILING DATE: 2003-03-27
; CURRENT APPLICATION NUMBER: US10/335,053
; CURRENT FILING DATE: 2003-03-27
; PRIORITY APPLICATION NUMBER: 60/345,317
; PRIORITY FILING DATE: 2001-12-31
; NUMBER OF SEQ ID NOS: 319
; SOFTWARE: Patentin version 3.2
; SEQ ID NO: 291
; LENGTH: 2732
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-335-053-291

Query Match 99.5%; Score 214; DB 18; Length 2732;
Best Local Similarity 100%; Pred. No. 2.4e-60; Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1 ATAACGGCTAGCCTGAGGAGCTGCTGGACAGTCACCTTTGAGAGTGTACTCC	60
Db	274 ATAACGGCTAGCCTGAGGAGCTGCTGGACAGTCACCTTTGAGAGTGTACTCC	333
Qy	61 GTGTGTCGCAAGGCTTCAGACGAACTGTCGGCTCAGGACCGGGCTGAGTT	120
Db	334 GTGTGTCGCAAGGCTTCAGACGAACTGTCGGCTCAGGACCGGGCTGAGTT	393
Qy	121 CGGGCGTCCGAGGAGGACGAGCTCTTCGGGATCGAGTTCGGTTCCAGCCCCAA	180

```

Db 394 CCGGGCCTCCGGAGAGGACGACTCTTCTCGGGATCCAGTTCCAGCCCCAA 453
Qy 181 TCTCAGAGCCGAGCCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 214
Db 454 TCTCAGAGCCGAGCCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 487

RESULT 2
US-10-348-359-1
; Sequence 1, Application US/10348359
; Publication No. US20040018178A1
; GENERAL INFORMATION:
; APPLICANT: WEST, MICHAEL
; TITLE OF INVENTION: STEM CELL-DERIVED ENDOTHELIAL CELLS MODIFIED TO DISRUPT
; FILE REFERENCE: 100375_54374US
; CURRENT APPLICATION NUMBER: US/10/348,359
; PRIORITY FILING DATE: 2002-01-22
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO: 1
; LENGTH: 549
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-348-359-1

Query Match 99.3%; Score 213.4; DB 17; Length 549;
Best Local Similarity 99.5%; Pred. No. 3.4e-60;
Matches 214; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 ATAACGGCTAGCTGAGGAGCTGCTGGACACTTACCTTTCGAGAGTACTCCC 60
Db 269 ATAACGGCTAGCTGAGGAGCTGCTGGACACTTACCTTTCGAGAGTACTCCC 328
Qy 61 GPTGTGCTCAAAGCTTCCAGAGGCGAACCTGTGGGGCTGAGAGTACTCCC 120
Db 329 GTGTGCTCAAAGCTTCCAGAGGCGAACCTGTGGGGCTGAGAGTACTCCC 388
Qy 121 CGGGCGTCCGAGGACGAGGCGAGCTCTCTCGGGATCGAGTGTCCGTTTCAAGCCCCAA 180
Db 389 CGGGCGTCCGAGGACGAGGCGAGCTCTCTCGGGATCGAGTGTCCGTTTCAAGCCCCAA 448
Qy 181 TCTCAGAGCCGAGCCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 215
Db 449 TCTCAGAGCCGAGCCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 483

RESULT 3
US-10-108-260A-1023
; Sequence 1023, Application US/1008260A
; Publication No. US2004005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: NO. US2004005560A1el full length cDNA
; FILE REFERENCE: HI-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO: 1023
; LENGTH: 1903
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-108-260A-1023

Query Match 97.9%; Score 210.4; DB 17; Length 1903;
Best Local Similarity 99.5%; Pred. No. 3.6e-59;
Matches 211; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3 AACGGCTAGCTGAGGAGCTGCGGAGAGGCACTACTTTCGAGAGAGACTCCGT 62

```

```

Db 1 AACGGCTAGCTGAGGAGCTGCTGGACAGTCCACTACCTTTGAGAGTACTCCGT 60
Qy 63 TGTCCCAAGGCTTCCAGAGGAGACCTGTCGGCTGCGAGCACCGGGCTCGAATTC 122
Db 61 TGTCCCAAGGCTTCCAGAGGAGACCTGTCGGCTGCGAGCACCGGGCTCGAATTC 120
Qy 123 GGCGRGGAGGAGGAGGAGCTTCCAGGGTTCCAGCCCCAATC 182
Db 121 GGCGRGGAGGAGGAGGAGCTTCCAGGGTTCCAGCCCCAATC 180
Qy 183 TCAGAGCCGAGCCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 214
Db 181 TCAGAGCCGAGCCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 212

RESULT 4
US-10-172-118-1144
; Sequence 1144, Application US/10172118
; Publication No. US20030224374A1
; GENERAL INFORMATION:
; APPLICANT: Dai, Hongrue
; APPLICANT: He, Yudong
; APPLICANT: Linsley, Peter
; APPLICANT: Mao, Mao
; APPLICANT: Roberts, Chris
; APPLICANT: Van de Vijver, Marc
; APPLICANT: Bernards, Rene
; APPLICANT: He, Yudong
; TITLE OF INVENTION: Diagnosis and Prognosis of Breast Cancer Patients
; FILE REFERENCE: 9301-175-999
; CURRENT APPLICATION NUMBER: US/10/172,118
; PRIORITY FILING DATE: 2002-05-14
; NUMBER OF SEQ ID NOS: 2699
; SEQ ID NO: 1144
; LENGTH: 2387
; TYPE: DNA
; ORGANISM: Homo sapiens
; PUBLICATION INFORMATION:
; DATABASE ACCESSION NUMBER: NM_005345
; DATABASE ENTRY DATE: 2001-06-18
; US-10-172-118-1144

Query Match 90.7%; Score 195; DB 17; Length 2387;
Best Local Similarity 100.0%; Pred. No. 4.2e-54;
Matches 195; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 20 GCTGCTGGAGAGTCACTACCTTTGAGAGTACTCCGGTGGCCAGGCTCCCA 79
Db 1 GCTGCTGGAGAGTCACTACCTTTGAGAGTACTCCGGTGGCCAGGCTCCCA 60
Qy 80 GAGCGAACTCTGCGCGCTGAGGAGCGGGCGTGGAGATTCGCGCGTCCGGAGAACCG 139
Db 61 GAGCGAACTCTGCGCGCTGAGGAGCGGGCGTGGAGATTCGCGCGTCCGGAGAACCG 120
Qy 140 AGCTCTCTCGGGATCAGTGTTCGTTTCAGCCCCAATCTAGAGCGAGCGACA 199
Db 121 AGCTCTCTCGGGATCAGTGTTCGTTTCAGCCCCAATCTAGAGCGAGCGACA 180
Qy 200 GAGAGCGGGAACCG 214
Db 181 GAGAGCGGGAACCG 195

RESULT 5
US-10-342-887-1144
; Sequence 1144, Application US/10342887
; Publication No. US20040058340A1
; GENERAL INFORMATION:
; APPLICANT: Dai, Hongrue
; APPLICANT: He, Yudong
; APPLICANT: Linsley, Peter S.

```

```

APPLICANT: Mao, Mao
APPLICANT: Robert, Christopher J.
APPLICANT: Van 't Veer, Laura Johanna
APPLICANT: Van de Vijver, Marc J.
APPLICANT: Bemis, Rene
TITLE OF INVENTION: Diagnosis and Prognosis of Breast Cancer Patients
FILE REFERENCE: 9301-188-999
CURRENT APPLICATION NUMBER: US/10/342,887
CURRENT FILING DATE: 2003-01-15
PRIORITY APPLICATION NUMBER: 60/288,918
PRIORITY FILING DATE: 2001-05-18
PRIORITY APPLICATION NUMBER: 60/380,710
PRIORITY FILING DATE: 2002-05-14
PRIORITY APPLICATION NUMBER: 10/172,118
PRIORITY FILING DATE: 2002-05-14
NUMBER OF SEQ ID NOS: 2699
SEQ ID NO: 1144
LENGTH: 2387
TYPE: DNA
ORGANISM: Homo sapiens
; US-10-342-887-1144

Query Match 90.7%; Score 195; DB 17; Length 2387;
Best Local Similarity 100.0%; Pred. No. 4.2e-54;
Matches 195; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
TITLE OF INVENTION: Diagnosis and Prognosis of Breast Cancer Patients
FILE REFERENCE: 9301-188-999
CURRENT APPLICATION NUMBER: US/10/342,887
CURRENT FILING DATE: 2003-01-15
PRIORITY APPLICATION NUMBER: 60/288,918
PRIORITY FILING DATE: 2001-05-18
PRIORITY APPLICATION NUMBER: 60/380,710
PRIORITY FILING DATE: 2002-05-14
PRIORITY APPLICATION NUMBER: 10/172,118
PRIORITY FILING DATE: 2002-05-14
NUMBER OF SEQ ID NOS: 2699
SEQ ID NO: 1144
LENGTH: 2387
TYPE: DNA
ORGANISM: Homo sapiens
; US-10-342-887-1144

RESULT 7
US-10-029-386-6557/C
; Sequence 6557, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
APPLICANT: Penn, Sharon G.
APPLICANT: Rank, David R.
APPLICANT: Hanzel, David K.
TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USED
FILE REFERENCE: AEOMICCA-X-2
CURRENT APPLICATION NUMBER: US/10/029,386
CURRENT FILING DATE: 2001-12-20
NUMBER OF SEQ ID NOS: 34288
SOFTWARE: Annamax Sequence Listing Engine vers. 1.1
SEQ ID NO: 6557
LENGTH: 506
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: MAP TO AF114726.1
OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 5.5
OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 4.8
OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 3.1
OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 11
OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 7.9
OTHER INFORMATION: SWISSPROT HIT: P08107, EVALUE 2.00e-17
OTHER INFORMATION: NT HIT: M59330.1, EVALUE 0.00e+00
OTHER INFORMATION: EST_HUMAN HIT: BE773197.1, EVALUE 0.00e+00
; US-10-029-386-6557

Query Match 76.1%; Score 163.6; DB 16; Length 506;
Best Local Similarity 88.1%; Pred. No. 7.9e-44;
Matches 178; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES
FILE REFERENCE: PA-0035 US
CURRENT APPLICATION NUMBER: US/09/919,039
CURRENT FILING DATE: 2002-09-09
PRIORITY APPLICATION NUMBER: 60/222,113
PRIORITY FILING DATE: 2000-07-28
NUMBER OF SEQ ID NOS: 401
SOFTWARE: PERL Program
SEQ ID NO: 144
LENGTH: 2412
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
OTHER INFORMATION: Incyte ID No. US20030108871A1 242010.16
; US-09-919-039-144

RESULT 8
US-10-425-115-89981
; Sequence 89981, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
APPLICANT: La Rosa, Thomas J.
APPLICANT: Kovalic, David K.

```

```

; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(5322)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO: 89981
; LENGTH: 284
; TYPE: DNA
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MIR457_182065C.1
; US-10-425-115-89981

Query Match 73.6%; Score 158.2; DB 18; Length 284;
Best Local Similarity 95.3%; Pred. No. 4.5e-42; Indels 0; Gaps 0;
Matches 163; Conservative 0; Mismatches 8; SEQ ID NO: 290
Db 1 TTTCAGAGTGTGACTCCGGTTCAGAGGCTTCAGAGGCTTCAGAGGACCTCTGCGGCTGAGGA 104
Db 121 CGTTCCAGCCCCAAATCTCATAGCGGAGCAGATAGAGGATTCGG3C 171
Db 61 CGGGCGGTCCAGTTCCGGGTCAGACCGACTCTCGGGATTCAGITC 120
Db 165 CGTTCCAGCCCCAAATCTCAGAGGCTTCAGAGGACCTCTGCGGCTGAGGA 60

Qy 105 CGGGCGGTCCAGTTCCGGGTCAGACCGACTCTCGGGCTGAGGA 164
Qy 165 CGTTCCAGCCCCAAATCTCAGAGGCTTCAGAGGACCTCTGCGGCTGAGGA 215
Db 121 CGTTCCAGCCCCAAATCTCATAGCGGAGCAGATAGAGGATTCGG3C 171
Db 61 CGGGCGGTCCAGTTCCGGGTCAGACCGACTCTCGGGATTCAGITC 120
Db 165 CGTTCCAGCCCCAAATCTCAGAGGCTTCAGAGGACCTCTGCGGCTGAGGA 60

RESULT 9
; Sequence 145 Application US/09919039
; Publication No. US20030108871A1
; GENERAL INFORMATION:
; APPLICANT: Kaser, Matthew R
; TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES
; FILE REFERENCE: PA-0035 US
; CURRENT APPLICATION NUMBER: US/9/919,039
; CURRENT FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: 60/222,113
; NUMBER OF SEQ ID NOS: 401
; SOFTWARE: PRKL Program
; SEQ ID NO: 145
; LENGTH: 2458
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No. US20030108871A1 1678695CB1
; US-09-919-039-145

Query Match 72.9%; Score 156.8; DB 10; Length 2458;
Best Local Similarity 88.5%; Pred. No. 1.5e-41; Indels 0; Gaps 0;
Matches 170; Conservative 0; Mismatches 22; SEQ ID NO: 290
Db 11 GCCTGAGGAGCTCTGGACACTCCACTACTTTCAGAGTGATCCCTGGCTCAA 70
Db 1 GCCTGAGGAGCTCTGGACACTCCACTACTTTCAGAGTGATCCCTGGCTCAA 60
Qy 71 GCCTTCCAGGGAACTCTGGCTGGCGAGCTCCACTACTTTCAGAGTGATCCCTGGCTCAA 130
Qy 71 GCCTTCCAGGGAACTCTGGCTGGCGAGCTCCACTACTTTCAGAGTGATCCCTGGCTCAA 70
Db 61 GCCTTCCAGGGAACTCTGGCTGGCGAGCTCCACTACTTTCAGAGTGATCCCTGGCTCAA 120
Db 121 GAAGGCTGAGCTCTGGGATTCAGTGTTGGTTTCAGCCGAGATCTCGAGGC 180
Db 131 GAAGGCTGAGCTCTGGGATTCAGTGTTGGTTTCAGCCGAGATCTCGAGGC 190
Db 121 GAAGGCTGAGCTCTGGGATTCAGTGTTGGTTTCAGCCGAGATCTCGAGGC 180
Db 191 GAGCCCAAGAG 202
Db 181 GAGCCCAAGAG 192

RESULT 11
; Sequence 111980 Application US/10027632
; Publication No. US20020198371A1
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827-129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 111980
; US-10-027-632-111980/C
; Sequence 111980, Application US/10027632
; Publication No. US20020198371A1
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827-129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 111980

```


RESULT 15
 US-0-363-345A-20731/c
 ; Sequence 20731; Application US/10363345A.
 ; Publication No. US2004234960A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Alexander Olek
 ; APPLICANT: Christian Piepenbrock
 ; APPLICANT: Kurt Berlin
 ; TITLE OF INVENTION: Method for determining the degree of methylation of defined
 ; FILE REFERENCE: E01/122/
 ; CURRENT FILING DATE: 2003-03-03
 ; NUMBER OF SEQ ID NOS: 40712
 ; SEQ ID NO 20731
 ; LENGTH: 595
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: chemically treated genomic DNA (Homo sapiens)
 ; OTHER INFORMATION: CPG-island No: 20731
 ; US-10-363-345A-20731

Query Match 67.5%; Score 145.2; DB 18; Length 595;
 Best Local Similarity 79.9%; Pred. No. 8.9e-38; Matches 171; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

Qy 1 ATAACGCTACCTGAGGAGCTGCTCGACGTCTTACCTTTCGAGAGTGTCTCC 60
 Db 545 ATAAGCTTAACCTAAACACTTACGACATCCACTACCTTTTGCATAACTCCC 486
 Qy 61 GTGTGTCGAAGCTTCAGCGGACCTGTGGGTGCAAGCACCGGGGGTCGAGTT 120
 Db 485 GTTATCCAAACTTCCAAAGACAGACATAAGCTACGACATACACCGACGTCGAATT 426
 Qy 121 CGGGCGTCCAGGAGGAGCCAGCTCTCGGGATCAGTGTCCGTTCCAGCCCCAA 180
 Db 425 CGACGTCGAAAAACCGAATCTTCGGAATTCATATTCGGTTCCACCCCAA 366
 Qy 181 TCTCAGAGCCAGGCCAGAGCAGAGCAGGAGCCG 214
 Db 365 TCTCAAAACCGAACCGAACAAACAAACCG 332

Search completed: February 11, 2005, 09:47:21
 Job time : 265 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using SW model

Run on: February 11, 2005, 07:40:18 ; Search time 1641 Seconds
(without alignments)
4987.092 Million cell updates/sec

Title: US-09-936-506-1

Perfect score: 215

Sequence: 1 ataaacggcttagctggagag.....gacagagagcggaaacgc 215

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 68479088

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:*

1: gb_est1:*

2: gb_est2:*

3: gb_htc:*

4: gb_est3:*

5: gb_est4:*

6: gb_est5:*

7: gb_est6:*

8: gb_gss1:*

9: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	214	99.5	642	CN397686
2	214	99.5	2380	CR605652
3	214	99.5	2383	CP598680
4	214	99.5	2387	CR626292
5	214	99.5	2391	CR608110
6	214	99.5	2396	CP599258
7	214	99.5	2398	CR618761
8	214	99.5	2398	CR621778
9	214	99.5	2399	CR606872
10	214	99.5	2401	CR595673
11	214	99.5	2409	CR624878
12	214	99.5	2417	CR603812
13	212.4	98.8	356	CR612917
14	212.4	98.8	493	BR639435
15	212.4	98.8	511	CB154948
16	212.4	98.8	527	CB145118
17	212.4	98.8	590	CB138426
18	212.4	98.8	701	BR773197
19	212.4	98.8	816	BR485554
20	212.4	98.8	916	BR462679
21	212.4	98.6	582	BR350439
22	211.4	98.3	751	BR464037
23	211.4	98.1	570	BR259174
24	210.8	98.0	582	BP245573

ALIGMENTS

RESULT 1
CN397686
DEFINITION CN397686 16-MAY-2004
ACCESSION CN397686
VERSION GI:47385281
KEYWORDS EST
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
1 (bases 1 to 642)
REFERENCE 1 Brandenberger,R., Wei,H., Zhang,S., Lei,S., Murage,J., Fisk,G.J., Li,Y., Xu,C., Fang,R., Guegler,K., Rao,M.S., Mandalam,R., Lebkowski,J. and Stanton,L.W.
AUTHORS Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation
TITLE Nat. Biotechnol. 22 (6), 707-716 (2004)
COMMENT Contact: Brandenberger R
Regenerative Medicine
Geron Corporation
230 Constitution Drive, Menlo Park, CA 94025, USA
Tel: 650 473 8658
Fax: 650 473 7760
Email: rbrandenberger@geron.com
Insert Length: 642 Std Error: 0.00.
FEATURES Location/Qualifiers
SOURCE
1. 642
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/issue_type="embryonic stem cells, cell lines H1, H7, and H9"
/clone lib="GRN ES"
/note="oligo dT primed, full-length enriched cDNA library from undifferentiated H9 cell lines H1 (p32), H7 (p29), and H9 (p26) maintained in feeder-free conditions"
ORIGIN

Query Match 99.5%; Score 214; DB 7; Length 642;
Best Local Similarity 100.0%; Pred. No. 6.6e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 ATAACGGCTAGCCTGGAGAGTGTGCGACAGTCCACTACTTTCGAGAGTGTCTCC 60
Db 78 ATAACGGCTAGCCTGGAGAGTGTGCGACAGTCCACTACTTTCGAGAGTGTCTCC 137

QY	61	GTGTGCCAAGGCTTCCAGGCACTGTGCGCTGAGGACCTGTCAGGCTGAGTT	120	RESULT 2	CRS98680	full-length cDNA clone CS0D028Y15 of Neuroblastoma Cot 25-normalized of Homo Sapiens (human).	
Db	138	GTGTGCCAAGGCTTCCAGGCACTGTGCGCTGAGGACCTGTCAGGCTGAGTT	197	LOCUS	CRS98680	full-length cDNA clone CS0D028Y15 of Neuroblastoma Cot 25-normalized of Homo Sapiens (human).	
QY	121	CGCGGTCGAGGAGGAGCTCTCGGGATCCAGTGTCCGTTCCAGCCCCAA	180	DEFINITION	CRS98680	full-length cDNA clone CS0D028Y15 of Neuroblastoma Cot 25-normalized of Homo Sapiens (human).	
Db	198	CGCGGTCGAGGAGGAGCTCTCGGGATCCAGTGTCCGTTCCAGCCCCAA	257	ACCESSION	CRS98680	full-length cDNA clone CS0D028Y15 of Neuroblastoma Cot 25-normalized of Homo Sapiens (human).	
QY	181	TCTCAGAGCCGAGCCGAGAGAGCAGGAGAACCG	214	VERSION	CR626292.1	GI: 50507099	
Db	258	TCTCAGAGCCGAGCCGAGAGAGCAGGAGAACCG	291	KEYWORDS	HTC; CNSLT_CDNA.		
				SOURCE	Homo sapiens (human)		
				ORGANISM	Homo sapiens		
RESULT 2				REFERENCE	Bukarjota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Buterria; Primates; Catarrhini; Hominidae; Homo.		
CR60552				AUTHORS	1 (bases 1 to 2383)		
LOCUS	CR60552	2380 bp mRNA linear	HTC 21-JUL-2004	TITLE	Li, W.B., Gruber, C., Jesse, J. and Polayes, D.		
DEFINITION	full-length cDNA clone CS0D033YK03 of Fetal brain of Homo sapiens (human).			JOURNAL	Full-length cDNA libraries and normalization		
ACCESSION	CR60552			REMARK	Contract : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue		
VERSION	CR60552.1	GI: 50486459			2 (bases 1 to 2383)		
KEYWORDS	HTC; CNSLT_CDNA.						
SOURCE	Homo sapiens (human)						
ORGANISM	Homo sapiens						
REFERENCE	Bukarjota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Buterria; Primates; Catarrhini; Hominidae; Homo.			REFERENCE	Bukarjota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Buterria; Primates; Catarrhini; Hominidae; Homo.		
AUTHORS	1 (bases 1 to 2383)			AUTHORS	1 (bases 1 to 2383)		
TITLE	Li, W.B., Gruber, C., Jesse, J. and Polayes, D.			TITLE	Li, W.B., Gruber, C., Jesse, J. and Polayes, D.		
JOURNAL	Full-length cDNA libraries and normalization			JOURNAL	Full-length cDNA libraries and normalization		
REMARK	Contract : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue			REMARK	Contract : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue		
REFERENCE	1 (bases 1 to 2380)			REFERENCE	BP 191 9106 ERY cedex - FRANCE (E-mail : seqref@genoscope.cnrs.fr		
AUTHORS	Li, W.B., Gruber, C., Jesse, J. and Polayes, D.			AUTHORS	- Web : www.genoscope.cnrs.fr		
TITLE	Full-length cDNA libraries			TITLE	1st strand cDNA was primed with a NotI-oligo(dt) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and ECR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.		
JOURNAL	Unpublished			JOURNAL	Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 9106 ERY cedex - FRANCE (E-mail : seqref@genoscope.cnrs.fr		
COMMENT	Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue			COMMENT	- Web : www.genoscope.cnrs.fr		
REFERENCE	2 (bases 1 to 2380)			REFERENCE	1st strand cDNA was primed with a NotI-oligo(dt) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and ECR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.		
AUTHORS	Genoscope.			AUTHORS	Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 9106 ERY cedex - FRANCE (E-mail : seqref@genoscope.cnrs.fr		
TITLE	Direct Submission			TITLE	- Web : www.genoscope.cnrs.fr		
JOURNAL	Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 9106 ERY cedex - FRANCE (E-mail : seqref@genoscope.cnrs.fr			JOURNAL	1st strand cDNA was primed with a NotI-oligo(dt) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and ECR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.		
FEATURES	source			FEATURES	source		
FEATURES	1. 2380			FEATURES	1. 2383		
FEATURES	/organism="Homo sapiens"			FEATURES	/organism="Homo sapiens"		
FEATURES	/mol_type="mRNA"			FEATURES	/mol_type="mRNA"		
FEATURES	/db_xref="taxon:9606"			FEATURES	/db_xref="taxon:9606"		
FEATURES	/clone="CS0D033YK03"			FEATURES	/clone="CS0D033YK03"		
FEATURES	/tissue="retail brain"			FEATURES	/tissue="Neuroblastoma Cot 25-normalized"		
FEATURES	/plasmid="pCMVSPORT_6"			FEATURES	/plasmid="pCMVSPORT_6"		
ORIGIN				ORIGIN			
Query Match	99.5%	Score 214; DB 3; Length 2383;		Query Match	99.5%	Score 214; DB 3; Length 2383;	
Best Local Similarity	100.0%	Score 214; DB 3; Length 2383;		Best Local Similarity	100.0%	Score 214; DB 3; Length 2383;	
Matches	214;	Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Matches	214;	Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Db	1	ATAACGCTAGCTGAGGAGCTGCTGGACAGAGCTCCACTACCTTTGAGAGTGA	60	Db	1	ATAACGCTAGCTGAGGAGCTGCTGGACAGAGCTCCACTACCTTTGAGAGTGA	60
QY	1	ATAACGCTAGCTGAGGAGCTGCTGGACAGAGCTCCACTACCTTTGAGAGTGA	73	Db	14	ATAACGCTAGCTGAGGAGCTGCTGGACAGAGCTCCACTACCTTTGAGAGTGA	73
Db	14	ATAACGCTAGCTGAGGAGCTGCTGGACAGAGCTCCACTACCTTTGAGAGTGA	73	QY	61	GTGTGCCAAGGCTTCCAGGCACTGTGCGCTGAGGACCTGTCAGGCTGAGTT	120
QY	61	GTGTGCCAAGGCTTCCAGGCACTGTGCGCTGAGGACCTGTCAGGCTGAGTT	120	Db	74	GTGTGCCAAGGCTTCCAGGCACTGTGCGCTGAGGACCTGTCAGGCTGAGTT	133
Db	74	GTGTGCCAAGGCTTCCAGGCACTGTGCGCTGAGGACCTGTCAGGCTGAGTT	133	QY	181	TCTCAGAGCCGAGCCGAGAGAGCAGGAGAACCG	214
QY	121	CGCGGTCGAGGAGGAGCTCTCGGGATCCAGTGTCCGTTCCAGCCCCAA	180	Db	134	CGCGGTCGAGGAGGAGCTCTCGGGATCCAGTGTCCGTTCCAGCCCCAA	193
Db	134	CGCGGTCGAGGAGGAGCTCTCGGGATCCAGTGTCCGTTCCAGCCCCAA	193	QY	181	TCTCAGAGCCGAGCCGAGAGAGCAGGAGAACCG	214
QY	181	TCTCAGAGCCGAGCCGAGAGAGCAGGAGAACCG	214	Db	194	TCTCAGAGCCGAGCCGAGAGAGCAGGAGAACCG	227
Db	194	TCTCAGAGCCGAGCCGAGAGAGCAGGAGAACCG	227	RESULT 4	CR626292	2387 bp mRNA linear	
LOCUS	CR626292	HTC 21-JUL-2004		DEFINITION	CR626292	2387 bp mRNA linear	
DEFINITION	Full-length cDNA clone CS0D038YK03 of Fetal brain of Homo sapiens (human).			DEFINITION	Full-length cDNA clone CS0D038YK03 of Fetal brain of Homo sapiens (human).		
ACCESSION	CR626292			ACCESSION	CR626292		
VERSION	CR626292.1	GI: 50507099		VERSION	CR626292.1	GI: 50507099	
KEYWORDS	HTC; CNSLT_CDNA.			KEYWORDS	HTC; CNSLT_CDNA.		
SOURCE	Homo sapiens (human)			SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens			ORGANISM	Homo sapiens		

REFERENCE
 AUTHORS Li, W.B., Gruber,C., Jesse,J. and Polayes,D.
 TITLE Full-length cDNA libraries and normalization
 JOURNAL Unpublished
 REMARK Contact : Feng Liang Email : fliang@lifetech.com URL : <http://fulllength.invitrogen.com/> Invitrogen Corporation 1600
 Parady Avenue

REFERENCE
 AUTHORS 2 (bases 1 to 2387)
 TITLE Genoscope.
 JOURNAL Direct Submission

COMMENT Submitted (20-JUL-2004) Genoscope - Centre National de Sequençage : BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr - Web : www.genoscope.cns.fr)
 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and BCR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.

FEATURES
 SOURCE Location/Qualifiers

1. . 2387
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="SGDP038YK05"
 /tissue="T cells (Jurkat cell line) cot
 /clone="CSDP004Y01"
 /mol_type="mRNA"
 /tissue="fetal brain"
 /plasmid="pCMVSPORT_6"

ORIGIN

Query Match 99.5%; Score 214; DB 3; Length 2387;
 Best Local Similarity 100.0%; Pred. No. 7.9e-51;
 Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAACGCTAACCTGAGGAGTGTGGAGCTTCACTACCTTTCAGAGTGACTCC 60
 Db 14 ATAACGCTAACCTGAGGAGTGTGGAGCTTCACTACCTTTCAGAGTGACTCC 73

QY 61 GTTGTGCCAACGCTTCCAGAGGGAACTCTGGGGCTGAGGAGTGACTCC 120
 Db 74 GTTGTGCCAACGCTTCCAGAGGGAACTCTGGGGCTGAGGAGTGACTCC 133

QY 121 CGGGCTCCGAGGAGGACGACTCTCTGGGGATCAGTTTCCAGGCCCAA 180
 Db 134 CGGGCTCCGAGGAGGACGACTCTCTGGGGATCAGTTTCCAGGCCCAA 193

QY 181 TCTCAGAGCCGAGCCGACAGAGCAGGGACCG 214
 Db 194 TCTCAGAGCCGAGCCGACAGAGCAGGGACCG 227

RESULT 5
 CR608110 CR608110 2391 bp mRNA linear HTC 21-JUL-2004
 LOCUS CR608110
 DEFINITION full-length cDNA clone CS0004Y01 of T cells (Jurkat cell line)
 ACCESSION CR608110
 VERSION GI:50488917
 KEYWORDS HRC; CNSLT cDNA.
 SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
 AUTHORS Li, W.B., Gruber,C., Jesse,J. and Polayes,D.
 TITLE JOURNAL
 REMARK Unpublished
 Contact : Feng Liang Email : fliang@lifetech.com URL : <http://fulllength.invitrogen.com/> Invitrogen Corporation 1600
 Parady Avenue

REFERENCE
 AUTHORS 2 (bases 1 to 2396)
 TITLE Genoscope.
 JOURNAL Direct Submission

COMMENT Submitted (20-JUL-2004) Genoscope - Centre National de Sequençage : BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr - Web : www.genoscope.cns.fr)
 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and BCR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.

FEATURES
 SOURCE Location/Qualifiers

1. . 2391
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="SGDP004Y01"
 /tissue="T cells (Jurkat cell line) cot
 /clone="CSDP004Y01"
 /mol_type="mRNA"
 /tissue="fetal brain"
 /plasmid="pCMVSPORT_6"

ORIGIN

Query Match 99.5%; Score 214; DB 3; Length 2391;
 Best Local Similarity 100.0%; Pred. No. 7.9e-51;
 Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAACGCTAACCTGAGGAGTGTGGAGCTTCACTACCTTTCAGAGTGACTCC 60
 Db 29 ATAACGCTAACCTGAGGAGTGTGGAGCTTCACTACCTTTCAGAGTGACTCC 88

QY 61 GTTGTGCCAACGCTTCCAGAGGGAACTCTGGGGCTGAGGAGTGACTCC 120
 Db 89 GTTGTGCCAACGCTTCCAGAGGGAACTCTGGGGCTGAGGAGTGACTCC 148

QY 121 CGGGCTCCGAGGAGGACGACTCTCTGGGGATCAGTTTCCAGGCCCAA 180
 Db 149 CGGGCTCCGAGGAGGACGACTCTCTGGGGATCAGTTTCCAGGCCCAA 208

QY 181 TCTCAGAGCCGAGCCGACAGAGCAGGGACCG 214
 Db 209 TCTCAGAGCCGAGCCGACAGAGCAGGGACCG 242

RESULT 6
 CR59258 CR59258 2396 bp mRNA linear HTC 21-JUL-2004
 LOCUS CR59258
 DEFINITION full-length cDNA clone CS0DP007Y19 of Fetal brain of Homo sapiens (human).
 ACCESSION CR59258
 VERSION GI:50480065
 KEYWORDS HRC; CNSLT cDNA.
 SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
 AUTHORS Li, W.B., Gruber,C., Jesse,J. and Polayes,D.
 TITLE JOURNAL
 REMARK Unpublished
 Contact : Feng Liang Email : fliang@lifetech.com URL : <http://fulllength.invitrogen.com/> Invitrogen Corporation 1600
 Parady Avenue

REFERENCE
 AUTHORS 2 (bases 1 to 2396)
 TITLE Genoscope.
 JOURNAL Direct Submission

COMMENT Submitted (20-JUL-2004) Genoscope - Centre National de Sequençage : BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr - Web : www.genoscope.cns.fr)
 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and BCR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.

FEATURES
 SOURCE Location/Qualifiers

1. . 2396
 /organism="Homo sapiens"

Db	194	TCTCAGAGCCGAGCACAGGAGGGAGCCG	227	ORGANISM	Homo sapiens
RESULT	9			REFERENCE	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
CR66872	CR66872	full-length cDNA clone CS0DF021Y109	2399 bp mRNA	DEFINITION	(human)
LOCUS	CR66872		linear	ACCESSION	CR66872
DEFINITION			HTC 21-JUN-2004	VERSION	CR66872.1 GI:50487679
ACCESION				KEYWORDS	HTC; CNSLT_cDNA.
VERSION				SOURCE	Homo sapiens (human)
KEYWORDS				ORGANISM	Homo sapiens
SOURCE				REFERENCE	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
				AUTHORS	1 (bases 1 to 2401)
				TITLE	Li, W.B., Gruber,C., Jesse,J. and Polayes,D.
				JOURNAL	Full-length cDNA libraries and normalization
				REMARK	Unpublished
					Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue
					2 (bases 1 to 2401)
				REFERENCE	Genoscope.
				AUTHORS	Direct Submission
				TITLE	Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
				JOURNAL	BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
COMMENT					- Web : www.genoscope.cns.fr)
FEATURES					1st strand cDNA was primed with a NotI-oligo(dt) primer. Five prime
source					end enriched, double-strand cDNA was digested with Not I and cloned
					into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
					was normalized. Library was constructed by Life Technologies, a
					division of Invitrogen.
				FEATURES	Location/Qualifiers
				source	1. .2401
					/organism="Homo sapiens"
					/mol_type="mRNA"
					/db_xref="taxon:9606"
					/clone="CS0DF021Y109"
					/tissue_type="Placenta"
					/plasmid="pCMVSPORT_6"
				ORIGIN	
					Query Match 99.5%; Score 214; DB 3; Length 2399;
					Best Local Similarity 100.0%; Pred. No. 7.9e-51;
					Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1	ATAACCGCTTACCTGAGGAGCTGCTGAGCTACTACCTTTTGAGAGTGA	60	QY	1 ATAACCGCTTACCTGAGGAGCTGCTGAGCTACTACCTTTTGAGAGTGA
Db	14	ATAACCGCTTACCTGAGGAGCTGCTGAGCTACTACCTTTTGAGAGTGA	60	Db	29 ATAACCGCTTACCTGAGGAGCTGCTGAGCTACTACCTTTTGAGAGTGA
QY	61	GTTGTTCCCAAGGCTTCCAGGGACCTGTCGGGGTCAAGGACCGAC	120	QY	61 GTTGTTCCCAAGGCTTCCAGGGACCTGTCGGGGTCAAGGACCG
Db	14	GTTGTTCCCAAGGCTTCCAGGGACCTGTCGGGGTCAAGGACCGAC	120	Db	89 GTTGTTCCCAAGGCTTCCAGGGACCTGTCGGGGTCAAGGACCG
QY	74	GTTGTTCCCAAGGCTTCCAGGGACCTGTCGGGGTCAAGGACCGAC	133	Db	89 GTTGTTCCCAAGGCTTCCAGGGACCTGTCGGGGTCAAGGACCG
Db	121	CGGGCGTCCGAGAACGGAGCGAGCTCTCGGGATCCAGTGTCCGTT	180	QY	121 CGGGCGTCCGAGAACGGAGCGAGCTCTCGGGATCCAGTGTCCGTT
QY	134	CGGGCGTCCGAGAACGGAGCGAGCTCTCGGGATCCAGTGTCCGTT	193	Db	149 CGGGCGTCCGAGAACGGAGCTCTCGGGATCCAGTGTCCGTT
QY	181	TCTCAGAGCCGAGCCGAGAGGAGGACCG	214	QY	181 TCTCAGAGCCGAGCCGAGAGGAGGACCG
Db	194	TCTCAGAGCCGAGCCGAGAGGAGGACCG	227	Db	209 TCTCAGAGCCGAGCCGAGAGGAGGACCG
RESULT	11			REMARK	2409 bp mRNA linear HTC 21-JUN-2004
CR624878				DEFINITION	Full-length cDNA clone CS0DF012Y23 of Fetal brain of Homo sapiens
LOCUS	CR624878			ACCESSION	CR624878
DEFINITION				VERSION	CR624878.1 GI:50505685
ACCESION				KEYWORDS	HTC; CNSLT_cDNA.
VERSION				SOURCE	Homo sapiens (human)
KEYWORDS				ORGANISM	Homo sapiens
SOURCE				REFERENCE	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
				AUTHORS	1 (bases 1 to 2409)
				TITLE	Full-length cDNA libraries and normalization
				JOURNAL	Unpublished
				REMARK	Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue
RESULT	10			REFERENCE	2 (bases 1 to 2409)
CR595673	CR595673	2401 bp mRNA linear HTC 21-JUN-2004		AUTHORS	Genoscope.
LOCUS	CR595673	full-length cDNA clone CS0DE002YK13 of Placenta of Homo sapiens			
DEFINITION		(human).			
ACCESSION	CR595673				
VERSION	CR595673.1	GI:50476480			
KEYWORDS		HTC; CNSLT_cDNA.			
SOURCE		Homo sapiens (human)			

TITLE Direct Submission
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
 BP 191 91006 EVRY cedex - FRANCE (E-mail : segref@genoscope.cnrs.fr)
COMMENT - Web : www.genoscope.cnrs.fr
 1st strand cDNA was primed with a NotI-oligo(dt) primer. Five prime end enriched, double-strand cDNA was digested with NotI and cloned into the Not I and Bcor V sites of the PCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen. Location/Qualifiers

FEATURES source

1. 2409 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="CS00120X002"
 /tissue="Fetal brain"
 /plasmid="PCMVSPORT_6"
ORIGIN

Query Match 99.5%; Score 214; DB 3; Length 2409;
 Best Local Similarity 100.0%; Pred. No. 7.9e-51;
 Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATAACGGCTAGCTGAGGAGGTCTGGACACTCCACTACCTTTCGAGAGTGAATCC 60
 Db 14 ATAACGGCTAGCTGAGGAGGTCTGGACACTCCACTACCTTTCGAGAGTGAATCC 60
 Qy 61 GTTGTCTCCAAAGCTTCCAGAGGAGCTGTGGGCTGAGACGACCTGGGGCTGAGAGTGAATCC 73
 Db 74 GTTGTCTCCAAAGCTTCCAGAGGAGCTGTGGGGCTGAGACGACCTGGGGCTGAGAGTGAATCC 73
 Qy 121 CGGGCGAGCGAGGAGGAGCCGAGCTCTCTGGGATCCAGTGTCCGTTCCAGCCCAA 180
 Db 134 CGGGCGAGCGAGGAGGAGCCGAGCTCTCTGGGATCCAGTGTCCGTTCCAGCCCAA 193
 Qy 181 TCTCAGAGCCGAGCCGAGAGGAGGAGGAGCC 214
 Db 194 TCTCAGAGCCGAGCCGAGAGGAGGAGCC 227

RESULT 12

CR03812 C003812 2417 bp mRNA linear RNC 21-JUL-2004
LOCUS full-length cDNA clone CS0020Y002 of Fetal brain of Homo sapiens (human).
ACCESSION C003812
VERSION C003812.1 GI:50484619
KEYWORDS HTC; CNSHT_CDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 356)
AUTHORS Kim, Y.-S.
TITLE C1C Frontier Korean EST Project 2001
JOURNAL Unpublished (2002)
COMMENT Contact: Kim YS
 Genome Research Center
 Korea Research Institute of Bioscience & Biotechnology
 52, Baeum-dong Yuseong-gu, Daejeon 305-333, South Korea
 Tel: +82-42-860-4470
 Fax: +82-42-860-4409
 Email: yonggaung@mail.kribb.re.kr
 Plate: 10 row: A column: 11
 High quality sequence stop: 356.
 Location/Qualifiers

1. 356 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="16Ch0CK0-10-A11"
 /cell_line="CHO-CK"
 /lab_host="TOP10F"
 /clone_libr="16Ch0CK0"
 /note="Organ: Liver; Vector: PCNS-D2; Site_1: EcoRI; Site_2: NotI; The poly (A)+ RNA was dephosphorylated with bacterial alkaline phosphatase (BAP) and then decapped with tobacco acid pyrophosphatase (TAP). The decapped intact mRNA was ligated with DNA-RNA linker including EcoRI site by treatment of T4 RNA lase and the first strand cDNA was synthesized from oligo dT-selected mRNA by priming with dT-tailed vector. The dT-tailed vector was

FEATURES source

1. 2417 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="CS00120X002"
 /tissue="Fetal brain"
 /plasmid="PCMVSPORT_6"
ORIGIN

Query Match 99.5%; Score 214; DB 3; Length 2417;
 Best Local Similarity 100.0%; Pred. No. 7.9e-51;
 Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATAACGGCTAGCTGAGGAGGTCTGGACACTCCACTACCTTTCGAGAGTGAATCC 60
 Db 29 ATAACGGCTAGCTGAGGAGGTCTGGACACTCCACTACCTTTCGAGAGTGAATCC 60
 Qy 61 GTTGTCCAAAGCTTCCAGAGGAGCTGTGGGGCTGAGACGACCTGGGGCTGAGAGTGAATCC 120
 Db 89 GTTGTCCAAAGCTTCCAGAGGAGCTGTGGGGCTGAGACGACCTGGGGCTGAGAGTGAATCC 148
 Qy 121 CGGGCTCCGAGGAGGAGCTCTCGGATCCAGTGTCCGTTCCAGCCCAA 180
 Db 149 CGGGCTCCGAGGAGGAGCAGCTCTCGGATCCAGTGTCCGTTCCAGCCCAA 208
 Qy 181 TCTCAGAGCCGAGCCGAGAGGAGGAGGAGCC 214
 Db 209 TCTCAGAGCCGAGCCGAGAGGAGGAGCC 242

RESULT 13

CB112917 C003812 356 bp mRNA linear EST 28-JAN-2003
LOCUS K-EST0154803 L6Ch0CK0 Homo sapiens cDNA clone L6Ch0CK0-10-A11 5', mRNA Sequence.
ACCESSION CB112917
VERSION CB112917.1 GI:27938724
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Kim, Y.-S.
AUTHORS Oh, K.J., Cheong, J.E., Sohn, H.Y., Kim, J.M., Park, H.S., Kim, S. and Oh, K.J., Cheong, J.E., Sohn, H.Y., Kim, J.M., Park, H.S., Kim, S. and Kim, N.S., Hahn, Y., Oh, J.H., Lee, J.Y., Ahn, H.Y., Chu, M.Y., Kim, M.R., Kim, Y.S.
TITLE C1C Frontier Korean EST Project 2001
JOURNAL Unpublished (2002)
COMMENT Contact: Kim YS
 Genome Research Center
 Korea Research Institute of Bioscience & Biotechnology
 52, Baeum-dong Yuseong-gu, Daejeon 305-333, South Korea
 Tel: +82-42-860-4470
 Fax: +82-42-860-4409
 Email: yonggaung@mail.kribb.re.kr
 Plate: 10 row: A column: 11
 High quality sequence stop: 356.
 Location/Qualifiers

1. 356 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="16Ch0CK0-10-A11"
 /cell_line="CHO-CK"
 /lab_host="TOP10F"
 /clone_libr="16Ch0CK0"
 /note="Organ: Liver; Vector: PCNS-D2; Site_1: EcoRI; Site_2: NotI; The poly (A)+ RNA was dephosphorylated with bacterial alkaline phosphatase (BAP) and then decapped with tobacco acid pyrophosphatase (TAP). The decapped intact mRNA was ligated with DNA-RNA linker including EcoRI site by treatment of T4 RNA lase and the first strand cDNA was synthesized from oligo dT-selected mRNA by priming with dT-tailed vector. The dT-tailed vector was

adjusted to have about 60nt. The cDNA vector was circularized with *E. coli* DNA ligase after digestion of EcoRI which site is also included in vector. An RNA strand converted to a DNA strand by Okayama-Berg method. The obtained cDNA vectors were used for transformation of competent cells *E. coli* Top10^R by electroporation method. The cDNA libraries constructed by this method are full-length enriched cDNA library.

OPTIM

was dissected from two 80 year old donors with no observed eye disease. 100ug of total RNA was used for library construction. A directionally cloned cDNA library in the pSPORT1 vector (Life Technologies) was constructed at Bioservive Biotechnology (Laurel, MD) essentially following the protocols of the SuperScript Plasmid System full details of which are contained in the manufacturer's instruction manual (<http://www.lifetech.com/>). First strand synthesis was carried out using a Not I primer-adapter [5'-*PGACATGTTCTGAGTCGGAGGCCGCC(T)15-3'*]. EST analysis was performed on the unamplified library at the NIH Intramural Sequencing Center (NSC) ".

Query	Match	98.8%	Score	212.4	Length	356
Best local Matches	Similarity	99.5%	Pred. No.	1.7e-50	Length	356
213;	Conservative	0;	Mismatches	1;	Indels	0;
Db	Qy	1	ATAAAGGCTAGCCCTAGGAGCTGCTGGACACTCCTACTACCTTTGAGAGCTGACTCC	60	Qy	1
Db	Qy	1	ATAAAGGCTAGCCCTAGGAGCTGCTGGACACTCCTACTACCTTTGAGAGCTGACTCC	60	Qy	1
Db	Qy	61	GTTCGCCAAGGCTTCCAGAGGAACCTGCGGTCAGGCCGGGGGGAGTT	120	Qy	61
Db	Qy	61	GTTCGCCAAGGCTTCCAGAGGAACCTGCGGTCAGGCCGGGGGGAGTT	120	Qy	121
Db	Qy	121	CGGGGTCCGAAGGACCGAGCTTCTCGCGGATCCAGGTCTGGTTCAGGCCCCAA	180	Qy	121
Db	Qy	121	CGGGGTCCGAAGGACCGAGCTTCTCGCGGATCCAGGTCTGGTTCAGGCCCCAA	180	Qy	181
Db	Qy	181	TCTCAGGCGAGCGACAGAGAGCGAGCTCTCTCGGGATTCAGTGTCTCGGTTCCAGCCCCAA	214	Qy	181
Db	Qy	181	TCTCAGGCGAGCGACAGAGAGCGAGCTCTCTCGGGATTCAGTGTCTCGGTTCCAGCCCCAA	214	Qy	181

RESULT 14
BQ639435

DEFINITION himself-1 Human Retina cDNA (Un-normalized, unamplified); hd/he
ACCESSION Homo sapiens cDNA clone hel5e11 5', mRNA sequence.
KEYWORDS EST.
ORGANISM Homo sapiens (human)
SOURCE Homo sapiens
REFERENCE 1 (bases 1 to 493)
AUTHORS Wistow, G., Bernstein, S.L., Wyatt, M.K., Ray, S., Behal, A., Touchman, J.W., Bouffard, G., Smith, D. and Peterson, K.
TITLE Expressed sequence tag analysis of human retina for the NEIBank Project: Retinobin, an abundant, novel retinal cDNA and alternative splicing of other retina-preferred gene transcripts
JOURNAL Mol. Vis. 8 (4), 196-204 (2002)
MEDLINE 22103461
PUBMED 12107411
COMMENT
Contact: Wistow G
Section on Molecular Structure and Function
National Eye Institute
6/331, NIH, Bethesda, MD 20892-2740, USA
Tel: 301 402 3452
Fax: 301 496 0078
Email: graeme@helix.nih.gov
Plate: 15 row: e column: 11
Seq primer: M13RPL reverse primer (ABR).
Location/Qualifiers
1. 493
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="hel5e11"
/tissue_type="retina"
/dev_stage="Adult"
/lab_host="EMDH10B"
/clone_id="Human Retina cDNA (Un-normalized,
unamplified): hd/he"
/notes="Organ: Eye; Vector: pSPORT1; Neural retina tissue

primer-adapter 5'-TGACTGTCAGTCGGAGGCCGCC(T)15-3']. EST analysis was performed on the unamplified library at the NIH Intramural Seminar (NISC) ".

Query	Match	Score	DB	Length
Qy	1 ATAAAGGCTAGCCAGAGGCTGCTGGAGCAGTCCTACACTTTCAGAGTGTCTCC	98.8%	5	493;
Best: Local Similarity	99.5%	Pred. No.	1.8e-50;	
Matches	213;	Mismatches	0;	
Qy	10 ATAAAGGCTAGCCAGAGGCTGCTGGAGCAGTCCTACACTTTCAGAGTGTCTCC	99.5%	5	493;
Db	61 GTTGTTCCAGAGCTTCCAGAGCGAACCTTGCGCTCGAGCACGGCGGGTCTCAGTT	99.5%	6	493;
Qy	61 GTTGTTCCAGAGCTTCCAGAGCGAACCTTGCGCTCGAGCACGGCGGGTCTCAGTT	99.5%	6	493;
Db	70 GTTGTTCCAGAGCTTCCAGAGCGAACCTTGCGCTCGAGCACGGCGGGTCTCAGTT	99.5%	6	493;
Qy	121 CCGGGCTCGGAAGGACCGACTCTCTGGGATCCAGTGTTCGTTTCAGCCCCAA	99.5%	6	493;
Db	130 CCGGGCTCGGAAGGACCGACTCTCTGGGATCCAGTGTTCGTTTCAGCCCCAA	99.5%	6	493;
Qy	189 CCGGGCTCGGAAGGACCGACTCTCTGGGATCCAGTGTTCGTTTCAGCCCCAA	99.5%	6	493;

Site 2: NotI: The poly (A)+ RNA was dephosphorylated with bacterial alkaline phosphatase (BAP) and then decapped with tobacco acid pyrophosphatase (TAP). The decapped intact mRNA was ligated with DNA-RNA linker including EcoRI site by treatment of λ RNA ligase and the first strand cDNA was synthesized from oligo dT-selected mRNA by priming with dT-tailed vector. The dT-tailed vector was adjusted to have about 60nt. The cDNA vector was circularized with E. coli DNA ligase after digestion of EcoRI which site is also included in vector. An RNA strand converted to a DNA strand by Okazama-Berg method. The obtained cDNA vectors were used for transformation of competent cells E. coli Top10F' by electroporation method. The cDNA libraries constructed by this method are full-length enriched cDNA library."

ORIGIN

Query Match 98.8%; Score 212.4; DB 6; Length 511;
 Best Local Similarity 99.5%; Pred. No. 1.8e-50;
 Matches 213; Conservatism 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1 ATAACGGCTAACCTGAGGAGTGTCTGGACAGTCCACTACCTTTTGAGAGTGACTCCC 60
 Db 1 ATAACGGCTAACCTGAGGAGTGTCTGGACAGTCCACTACCTTTTGAGAGTGACTCCC 60
 Qy 61 GGTGTCCTAACGCTTCCAGGGGAACTGTGGGGCTGAGCAGCACGGCGCTCGAGTT 120
 Db 61 GGTGTCCTAACGCTTCCAGGGGAACTGTGGGGCTGAGCAGCACGGCGCTCGAGTT 120
 Qy 121 CGGGGTCCGGAGGAGGCGAGGCGCTTCTGGGGATCCAGTCTCCGTTCAAGCCCCAA 180
 Db 121 CGGGGTCCGGAGGAGGCGAGGCGCTTCTGGGGATCCAGTCTCCGTTCAAGCCCCAA 180
 Qy 181 TCTCAGAGCCGAGCCGACAGGAGGAGCAGGGAAACCG 214
 Db 181 TCTCAGAGCCGAGCCGACAGGAGGAGCAGGGAAACCG 214

Search completed: February 11, 2005, 09:02:43
 Job time : 1646 secs